Anti-human papilloma virus (HPV) antigen binding proteins and methods of use thereof
By developing antigen-binding proteins that specifically bind HLA-display HPV16E7 peptide, the shortcomings in the treatment of HPV-induced cancer in the prior art were solved, targeted killing and high-sensitivity diagnosis of HPV16E7 presenting cells were achieved, and more effective treatment was provided and diagnostic means.
Patent Information
- Application Number
- CN202410994510.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-06-28
- Filing Date
- 2018-06-27
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively target and treat cervical cancer and other cancers caused by human papillomavirus (HPV). Traditional treatments are highly invasive and have limited effectiveness in patients with advanced or recurrent lesions.
Antigen-binding proteins were developed that specifically bind HLA-displayed HPV16E7 peptide to target HPV16E7 presenting cells, activate T cells, and for high-sensitivity diagnostic and prognostic measures of disease progression. The antigen-binding protein may be an antibody or an antigen-binding fragment thereof, with high affinity and specificity, and is able to specifically bind to HLA-A2:HPV16E7 11-19 or 82-90 peptide complex.
Targeted killing of HPV16E7 presenting cells has been achieved, the therapeutic effect on HPV-related cancers has been improved, and a high-sensitivity diagnostic and prognostic tool is provided, especially in patients with advanced or recurrent lesions.
Smart Images

Figure SMS_7 
Figure SMS_8 
Figure SMS_9
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of June 27, 2018, application number 201880044309.7, and invention name “Anti-human papillomavirus (HPV) antigen binding protein and method of use thereof”.
[0002] Related Applications
[0003] This application claims priority to U.S. Provisional Application No. 62 / 525,937, filed on June 28, 2017, the entire contents of which are expressly incorporated herein by reference in their entirety.
[0004] Sequence Listing
[0005] This application contains a sequence listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy was created on June 27, 2018, named 10355WO01_seqlisting.txt, and is 253,600 bytes in size. Technical Field
[0006] The present invention relates to antigen binding proteins that specifically bind to HLA-displaying human papillomavirus (HPV) peptides, and therapeutic and diagnostic methods using these binding proteins. Background Art
[0007] Human papillomavirus (HPV) is a group of small, non-enveloped DNA viruses that are very common worldwide. HPV is mainly transmitted through sexual contact, and most people become infected with HPV soon after having sex.
[0008] There are more than 170 types of HPV, some of which can cause warts or benign papillomas, while at least 13 of the others cause cancer (also called high-risk HPV), including cervical cancer, anorectal cancer (cancers of the anus, penis, vagina, and vulva), head / neck cancer, and oropharyngeal cancer, which includes the back of the throat, base of the tongue, and tonsils. In fact, HPV is present in 20-40% of all head and neck squamous cell carcinomas (HNSCC) and in 100% of cervical cancers.
[0009] Cervical cancer is the second most common cancer among women living in less developed regions, with an estimated 445,000 new cases (84% of new cases worldwide) in 2012. Approximately 270,000 women died from cervical cancer in 2012; more than 85% of these deaths occurred in low- and middle-income countries.
[0010] Two HPV types (16 and 18) cause about 70% of all cervical cancers and precancerous cervical lesions. Cancer development during persistent infection with high-risk HPV subtypes such as HPV 16 or 18 can be attributed primarily to the expression of two viral tumor proteins, E6 and E7, which are persistently expressed in lesions and presented on the cell surface via MHC class I, but not expressed in normal cells. E6 and E7 promote genomic instability and cell transformation by degrading tumor suppressor proteins p53 and Rb in a proteasome-dependent manner. Tumors appear several years after the initial cell immortalization event, and the continued expression of E6 and E7 is required to maintain the transformed phenotype and prevent cell growth arrest and / or apoptosis (McLaughlin-Drubin ME & Miinger K., Virology (2009) 384: 335-344).
[0011] Although vaccines targeting the HPV L1 and L2 major capsid proteins of HPV-6, -11, -16 and -18 subtypes have been developed to prevent infection, such vaccines cannot treat subjects with established lesions. Therefore, treatment of subjects with cervical cancer remains to use traditional methods, which are highly invasive and morbid, such as surgery, radiotherapy and chemotherapy. In addition, although such treatments can provide benefits to subjects with early-stage cervical cancer, they are of limited value for patients with advanced or recurrent cervical cancer.
[0012] Therefore, there is an unmet need in the art for new therapeutic strategies to target HPV with high specificity and treat cervical cancer and other cancers caused by HPV. Summary of the invention
[0013] The present invention provides antigen binding proteins that specifically bind to conformational epitopes of HLA-displaying human papillomavirus (HPV) 16E7 peptides (HLA-A2: HPV16E7). The antigen binding proteins of the present invention highly specifically bind to HLA displaying HPV16E7, and do not bind to HLA display peptides that differ by 1, 2, 3, 4, 5 or more amino acids. The antigen binding proteins of the present invention allow specific targeting of HPV16E7 peptide presenting cells (i.e., cells presenting HPV16E7 peptides bound to MHC molecules on their surface, e.g., HLA-A2), such as cancer cells expressing HPV16E7, and in some embodiments, stimulate T cell activation, e.g., to stimulate T cell-mediated killing of such cells. In addition, when fused to a detectable portion, the antigen binding proteins of the present invention allow for high sensitivity diagnosis and prognosis of HPV16E7-positive diseases or conditions with changes in the number and distribution of HPV16E7 peptide presenting cells (a measure of disease progression that is more relevant than circulating HPV16E7 levels).
[0014] The antigen binding proteins of the present invention can be antibodies, such as full-length (e.g., IgG1 or IgG4 antibodies), or can include only the antigen binding portion of an antibody (e.g., Fab, F(ab')2 or scFv fragments), and can be modified to affect functionality, for example, to eliminate residual effector functions (Reddy et al., 2000, J. Immunol. 164: 1925-1933). In some embodiments, the antigen binding proteins of the present invention can be antibodies or antigen binding fragments thereof. In certain embodiments, the antigen binding proteins can be bispecific.
[0015] In a first aspect, the present invention provides an isolated recombinant antigen binding protein that specifically binds to a conformational epitope of an HLA-displayed human papillomavirus (HPV) 16E7 peptide, such as an HLA-displayed peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7. In certain embodiments, the antigen binding protein is an antibody. In some embodiments, the antibody is fully human.
[0016] Exemplary anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention are listed in Tables 1 and 2 herein. Table 1 lists the amino acid sequence identifiers of the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementary determining region (HCDR1, HCDR2 and HCDR3) and light chain complementary determining region (LCDR1, LCDR2) of exemplary anti-HLA-A2:HPV16E7 antibodies. Table 2 lists the nucleic acid sequence identifiers of the HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of such exemplary anti-HLA-A2:HPV16E7 antibodies.
[0017] The present invention provides an antigen binding protein comprising a HCVR comprising an amino acid sequence selected from any one of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0018] The present invention also provides an antigen binding protein comprising a LCVR comprising an amino acid sequence selected from any one of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0019] The present invention also provides an antigen binding protein comprising a HCVR and LCVR amino acid sequence pair (HCVR / LCVR), comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides an antigen binding protein comprising a HCVR / LCVR amino acid sequence pair contained in any of the exemplary anti-HLA-A2: HPV16E7 antigen binding proteins listed in Table 1. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from SEQ ID NO:2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 2 74, 282 / 290, 298 / 306, 314 / 322, 330 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514 and 522 / 530. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from one of SEQ ID NO: 2 / 10 (e.g., H4sH17364N), 34 / 42 (e.g., H4sH17670P), 82 / 90 (e.g., H4sH17675P), 194 / 202 (e.g., H4sH17930N2), 282 / 290 (e.g., H4sH21064P) and 506 / 514 (e.g., H4sH17363N).
[0020] In certain embodiments, the present invention provides an anti-HLA-A2: HPV16E7 antigen binding protein comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence listed in Table 1 with no more than five amino acid substitutions, and the LCVR comprises an amino acid sequence listed in Table 1 with no more than five amino acid substitutions. For example, the present invention provides an anti-HLA-A2: HPV16E7 antigen binding protein comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 194 with no more than five amino acid substitutions, and the LCVR comprises an amino acid sequence of SEQ ID NO: 202 with no more than five amino acid substitutions. In another exemplary embodiment, the present invention provides an anti-HLA-A2: HPV16E7 antigen binding protein comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence of SEQ ID NO: 194 with at least one amino acid substitution, and the LCVR comprises an amino acid sequence of SEQ ID NO: 202 with at least one amino acid substitution.
[0021] The present invention also provides an antigen binding protein comprising a heavy chain CDR1 (HCDR1), wherein the HCDR1 comprises an amino acid sequence selected from the HCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0022] The present invention also provides an antigen binding protein comprising a heavy chain CDR2 (HCDR2), wherein the HCDR2 comprises an amino acid sequence selected from the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0023] The present invention also provides an antigen binding protein comprising a heavy chain CDR3 (HCDR3), wherein the HCDR3 comprises an amino acid sequence selected from the HCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0024] The present invention also provides an antigen binding protein comprising a light chain CDR1 (LCDR1), wherein LCDR1 comprises an amino acid sequence selected from the LCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0025] The present invention also provides an antigen binding protein comprising a light chain CDR2 (LCDR2), wherein the LCDR2 comprises an amino acid sequence selected from the LCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0026] The present invention also provides an antigen binding protein comprising a light chain CDR3 (LCDR3), wherein the LCDR3 comprises an amino acid sequence selected from the LCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0027] The present invention also provides an antigen binding protein comprising a HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3), which comprises any one of the HCDR3 amino acid sequences listed in Table 1 paired with any one of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides an antigen binding protein comprising a HCDR3 / LCDR3 amino acid sequence pair contained in any one of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from SEQ ID NO: 8 / 16 (e.g., H4sH17364N), 40 / 48 (e.g., H4sH17670P), 88 / 96 (e.g., H4sH17675P), 200 / 208 (e.g., H4sH17930N2), 288 / 296 (e.g., H4sH21064P) and 512 / 520 (e.g., H4sH17363N).
[0028] The present invention also provides an antigen binding protein comprising a HCVR and a LCVR, wherein the HCVR comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1, wherein the HCDR2 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1, and wherein the HCDR3 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1. In certain embodiments, the present invention provides an antigen binding protein comprising a HCVR and a LCVR, wherein the LCVR comprises LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1, wherein the LCDR2 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1, and wherein the LCDR3 comprises an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1. For example, the present invention provides an anti-HLA-A2:HPV16E7 antigen binding protein, which comprises a HCVR and a LCVR, wherein the HCVR comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence that differs from SEQ ID NO: 196 by 1 amino acid, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 198 or an amino acid sequence that differs from SEQ ID NO: 198 by 1 amino acid, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 200 or an amino acid sequence that differs from SEQ ID NO: 200 by 1 amino acid. In another exemplary embodiment, the present invention provides an antigen binding protein comprising a HCVR and a LCVR, wherein the LCVR comprises LCDR1, LCDR2 and LCDR3, wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:204 or an amino acid sequence that differs from SEQ ID NO:204 by 1 amino acid, the LCDR2 comprises the amino acid sequence of SEQ ID NO:206 or an amino acid sequence that differs from SEQ ID NO:206 by 1 amino acid, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:208 or an amino acid sequence that differs from SEQ ID NO:208 by 1 amino acid.
[0029] The present invention also provides an antigen binding protein comprising a set of six CDRs (ie, HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any one of the exemplary antigen binding proteins listed in Table 1. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence group is selected from SEQ ID NO: 4-6-8-12-14-16 (e.g., H4sH17364N), 36-38-40-44-46-48 (e.g., H4sH17670P), 84-86-88-92-94-96 (e.g., H4sH17675P), 196-198-200-204-206-208 (e.g., H4sH17930N2), 284-286-288-292-294-296 (e.g., H4sH21064P) and 508-510-512-516-518-520 (e.g., H4sH17363N).
[0030] In a related embodiment, the invention provides an antigen binding protein comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within a HCVR / LCVR amino acid sequence pair defined by any one of the exemplary antigen binding proteins listed in Table 1. For example, the present invention includes an antigen binding protein comprising a HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence group contained within a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10 (e.g., H4sH17364N), 34 / 42 (e.g., H4sH17670P), 82 / 90 (e.g., H4sH17675P), 194 / 202 (e.g., H4sH17930N2), 282 / 290 (e.g., H4sH21064P) and 506 / 514 (e.g., H4sH17363N).
[0031] Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within a given HCVR and / or LCVR amino acid sequence disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, for example, the Kabat definition, the Chothia definition, and the AbM definition. In general, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, for example, Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases can also be used to identify CDR sequences within antigen binding proteins.
[0032] The present invention includes anti-HLA-A2: HPV16E7 antigen binding proteins having modified glycosylation patterns. In some embodiments, modifications for removing undesirable glycosylation sites may be useful, or antibodies lacking fucose moieties present on oligosaccharide chains, for example, to increase antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al., (2002) JBC 277: 26733). In other applications, modifications of galactosylation may be performed to alter complement-dependent cytotoxicity (CDC).
[0033] In certain embodiments, the antigen binding protein of the invention is a monoclonal antibody comprising a HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising any one of the HCVR amino acid sequences listed in Table 1 paired with any one of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the monoclonal antibody comprises an Fc domain of an isotype selected from IgA, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, IgM and variants thereof.
[0034] The present invention provides an antigen binding protein or an antigen binding fragment thereof, which comprises a heavy chain comprising an amino acid sequence selected from any one of the HC amino acid sequences listed in Table 3, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0035] The present invention also provides an antigen binding protein or an antigen binding fragment thereof, which comprises a light chain, wherein the light chain comprises an amino acid sequence selected from any one of the LC amino acid sequences listed in Table 3, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0036] The present invention also provides an antigen binding protein or an antigen binding fragment thereof, comprising an HC and LC amino acid sequence pair (HC / LC), wherein the HC and LC amino acid sequence pair comprises any one of the HC amino acid sequences listed in Table 3 paired with any one of the LC amino acid sequences listed in Table 3. According to certain embodiments, the present invention provides an antibody or an antigen binding fragment thereof, comprising an HC / LC amino acid sequence pair contained in any one of the exemplary anti-PD-1 antibodies listed in Table 3. In certain embodiments, the HC / LC amino acid sequence pair is selected from SEQ ID NO: 578 / 579, 580 / 581, 582 / 583, 584 / 585, 586 / 587, 588 / 589, 590 / 591 and 592 / 593.
[0037] In a first aspect, the present invention provides an antigen binding protein or an antigen binding fragment thereof that binds to an HLA-peptide complex, wherein the antigen binding protein or its antigen binding fragment contacts at least 60%, at least 70%, at least 80% or at least 90% of the amino acid residues of the peptide contained in the HLA-peptide complex. In certain embodiments, the antigen binding protein or its antigen binding fragment "covers" or contacts all the amino acid residues of the peptide contained in the HLA-peptide complex. In certain embodiments, the antigen binding protein or its antigen binding fragment binds to the HLA-peptide complex with high affinity and specificity, wherein the antigen binding protein or its antigen binding fragment contacts the full length of the displayed peptide. As used herein, "contact" includes direct or water-mediated hydrogen bonds, charge-charge interactions or hydrophobic / van der Waals interactions. In one embodiment, the antigen binding protein or its antigen binding fragment binds to the HLA-A2-HPV16E7 11-19 peptide complex, wherein the antigen binding protein binds to at least 6 of the 10 amino acid residues of peptide 11-19 (SEQ ID NO: 538) and binds to HLA-A2, so that it completely covers the HLA-A2-peptide complex. In certain embodiments, the antigen binding protein or antigen binding fragment thereof comprises a CDR of a HCVR and a CDR of a LCVR, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1. In one embodiment, the antigen binding protein is fully human. In certain embodiments, the fully human antigen binding protein is not obtained using phage display methods and techniques. In one embodiment, the antigen binding protein comprises a light chain variable region of the IGKV1-39 subtype.
[0038] In certain embodiments, the present invention provides an antigen binding protein or an antigen binding fragment thereof that binds to the HLA-A2: HPV16E7 11-19 peptide, wherein the antigen binding protein binds to one or more amino acids of SEQ ID NO: 538. In one embodiment, the antigen binding protein binds to at least 6 amino acids of SEQ ID NO: 538. In one embodiment, the antigen binding protein binds to one or more amino acids selected from Y11, D14, L15, P17 and E18 of SEQ ID NO: 538.
[0039] In certain embodiments, the present invention provides an antigen binding protein that specifically binds to a conformational epitope of an HLA-A2 presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), wherein the conformational epitope comprises one or more amino acids of SEQ ID NO: 538. In certain embodiments, the conformational epitope comprises one or more amino acids selected from Y11, D14, L15, P17 and E18 of SEQ ID NO: 538.
[0040] The present invention also provides an antigen binding protein that competes with an antigen binding protein comprising a CDR of a HCVR and a CDR of a LCVR for specific binding to HLA-A2:HPV16E7, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0041] The present invention also provides an antigen binding protein that cross-competes for binding to HLA-A2:HPV16E7 with a reference antigen binding protein comprising a CDR of a HCVR and a CDR of a LCVR, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0042] The present invention also provides antigen binding proteins that bind to the same epitope as a reference antigen binding protein comprising a CDR of a HCVR and a CDR of a LCVR, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1. In certain embodiments, the present invention provides antigen binding proteins that bind to the same epitope as a reference antigen binding protein comprising a CDR of a HCVR and a CDR of a LCVR, wherein the HCVR is selected from the group consisting of SEQ ID NO: 2, 34, 82, 194, 282 and 504, and the LCVR is selected from the group consisting of SEQ ID NO: 10, 42, 90, 202, 290 and 514.
[0043] In one embodiment, the present invention provides an isolated recombinant antigen binding protein that specifically binds to a conformational epitope of HLA-A2 presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), wherein the antigen binding protein has a property selected from the following: (a) a binding dissociation equilibrium constant (K) of less than about 20 nM as measured in a surface plasmon resonance assay at 25°C; D ) binds to monomeric HLA-A2:HPV16E7 11-19 peptide; (b) has a binding dissociation equilibrium constant (K) of less than about 25 nM as measured in a surface plasmon resonance assay at 25°C. D ) binds to monomeric HLA-A2:HPV16E7 82-90 peptide; (c) binds to the peptide with an EC less than about 6 nM as determined by luminescence assay 50 binds to HLA-A2:HPV16E711-19 peptide-expressing cells and does not bind to cells expressing predicted off-target peptides; (d) has an EC of less than about 1 nM as determined by luminescence assay 50 binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide and does not substantially bind to cells expressing predicted off-target peptides; (e) has an EC of less than about 30 nM as determined by flow cytometry assay 50 (f) binds to HLA-A2:HPV16E7 11-19 peptide-expressing cells with an EC of less than about 75 nM as determined by flow cytometry assay. 50 Binding to HLA-A2: HPV16E7 82-90 peptide expressing cells; and (g) the conformational epitope comprises one or more amino acids of SEQ ID NO: 538. As disclosed elsewhere herein, an "off-target peptide" refers to a peptide that differs from a target peptide (e.g., HPV16 E7 11-19 peptide) by 1, 2, 3, 4, 5 or more amino acids.
[0044] In a second aspect, the present invention provides a nucleic acid molecule encoding an anti-HLA-A2: HPV16E7 antigen binding protein. For example, the present invention provides a nucleic acid molecule encoding any one of the HCVR amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0045] The present invention also provides nucleic acid molecules encoding any one of the LCVR amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.
[0046] The present invention also provides a nucleic acid molecule encoding any one of the HCDR1 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the HCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0047] The present invention also provides a nucleic acid molecule encoding any one of the HCDR2 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0048] The present invention also provides a nucleic acid molecule encoding any one of the HCDR3 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0049] The present invention also provides a nucleic acid molecule encoding any one of the LCDR1 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the LCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0050] The present invention also provides nucleic acid molecules encoding any one of the LCDR2 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0051] The present invention also provides nucleic acid molecules encoding any one of the LCDR3 amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto.
[0052] The present invention also provides a nucleic acid molecule encoding a HCVR, wherein the HCVR comprises a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid sequence set is defined by any one of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1.
[0053] The present invention also provides a nucleic acid molecule encoding a LCVR, wherein the LCVR comprises a set of three CDRs (i.e., LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is defined by any one of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1.
[0054] The present invention also provides nucleic acid molecules encoding both HCVR and LCVR, wherein the HCVR comprises an amino acid sequence of any one of the HCVR amino acid sequences listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any one of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any one of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any one of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes a HCVR and a LCVR, wherein both the HCVR and the LCVR are derived from the same anti-HLA-A2:HPV16E7 antigen binding protein listed in Table 1.
[0055] The present invention provides a nucleic acid molecule encoding any one of the heavy chain amino acid sequences listed in Table 3. The present invention also provides a nucleic acid molecule encoding any one of the light chain amino acid sequences listed in Table 3.
[0056] The present invention also provides a nucleic acid molecule encoding both a heavy chain (HC) and a light chain (LC), wherein the HC comprises an amino acid sequence of any one of the HC amino acid sequences listed in Table 3, and the LC comprises an amino acid sequence of any one of the LC amino acid sequences listed in Table 3.
[0057] In a related aspect, the present invention provides a recombinant expression vector capable of expressing a polypeptide comprising a heavy and / or light chain variable region of an anti-HLA-A2: HPV16E7 antigen binding protein. For example, the present invention includes a recombinant expression vector comprising any of the nucleic acid molecules mentioned above, i.e., a nucleic acid molecule encoding any of the HCVR, LCVR and / or CDR sequences described in Table 1. The present invention also provides a recombinant expression vector capable of expressing a polypeptide comprising a heavy and / or light chain of an anti-HLA-A2: HPV16E7 antigen binding protein. For example, the present invention includes a recombinant expression vector comprising any of the nucleic acid molecules mentioned above, i.e., a nucleic acid molecule encoding any of the heavy or light chain sequences described in Table 2. Also included within the scope of the present invention are host cells into which such a vector has been introduced, and methods for producing antigen binding proteins by culturing host cells under conditions that allow the production of antigen binding proteins, and recovering the antigen binding proteins so produced.
[0058] In a third aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of an isolated recombinant antigen binding protein that specifically binds to a conformational epitope of an HLA-A2-presenting HPV16E7 peptide (e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7), and a pharmaceutically acceptable carrier. In a related aspect, the present invention features a composition that is a combination of an anti-HLA-A2:HPV16E7 antigen binding protein and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with an anti-HLA-A2:HPV16E7 antigen binding protein. Exemplary agents that can be advantageously combined with anti-HLA-A2:HPV16E7 antigen binding proteins include, but are not limited to, other agents that bind and / or regulate HPV replication or infection (including other antibodies or antigen binding fragments thereof, etc.) and / or agents that regulate immune cell activation. Additional therapies that can be used in combination with the anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention are disclosed elsewhere herein.
[0059] In a fourth aspect, the present invention provides a method for treating a subject suffering from an HPV-related disease or condition, such as an HPV16E7-positive cancer. The method comprises administering to a subject in need thereof a therapeutically effective amount of an anti-HLA-A2 of the present invention: E7 antigen binding protein or pharmaceutical composition of the present invention. The disease treated is any disease or condition that is improved, alleviated, inhibited or prevented by the antigen binding proteins and compositions provided herein. In certain embodiments, the antigen binding proteins (or pharmaceutical compositions) of the present invention are administered to a subject in need thereof in combination with a second therapeutic agent. The second therapeutic agent may be selected from antibodies against T cell co-inhibitors, antibodies against tumor cell antigens, antibodies against T cell receptors, antibodies against epitopes on virus-infected cells, cytotoxic agents, anticancer drugs, antiviral drugs, anti-inflammatory drugs (e.g., corticosteroids), chemotherapeutic agents, surgery, radiotherapy, immunosuppressants, and any other drugs or therapies known in the art. In certain embodiments, the second therapeutic agent may be an agent that helps to offset or reduce any possible side effects associated with the antigen binding proteins of the present invention, if such side effects should occur.
[0060] In certain embodiments, the present invention provides methods for inhibiting the growth of HPV-related cancers. For example, the present invention provides methods for inhibiting the growth of tumors caused by primary tumors or metastatic tumors in subjects. In certain embodiments, the present invention provides methods for enhancing the survival (e.g., progression-free survival or overall survival) of subjects suffering from HPV-related cancers. Examples of cancers include, but are not limited to, squamous cell carcinomas, such as head and neck squamous cell carcinomas, cervical cancer, anorectal cancer, oropharyngeal cancer.
[0061] In certain embodiments, the invention provides methods for inhibiting or suppressing the growth of established tumors. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an antigen-binding protein of the invention. In certain embodiments, the antigen-binding protein is administered in combination with a second therapeutic agent.
[0062] Antigen binding proteins, such as antibodies, or antigen binding fragments thereof, can be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially. Antigen binding proteins, such as antibodies, or antigen binding fragments thereof, can be administered at a dose of about 0.1 mg / kg body weight to about 100 mg / kg body weight of the subject.
[0063] In a fifth aspect, the present invention provides isolated nucleic acid molecules encoding chimeric antigen receptors (CARs). The CAR may include a conformational epitope specifically binding to HLA-A2 presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), for example, an extracellular binding domain of amino acid residues 11-19 or 82-90 of HPV16E7, a transmembrane domain, and an intracellular signaling domain. In one embodiment, the extracellular binding domain is an anti-HLA-A2: HPV16E7 antigen binding protein or an antigen binding fragment thereof. The exemplary anti-HLA-A2: HPV16E7 antigen binding protein of the present invention is any one of the antigen binding proteins described herein.
[0064] For example, in certain embodiments, the antigen binding protein suitable for use in the CAR of the present invention comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained in any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained in any one of the light chain variable region (LCVR) sequences listed in Table 1.
[0065] In other embodiments, the antigen binding protein suitable for use in the CAR of the present invention comprises a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1; and / or a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
[0066] In some embodiments, the antigen binding protein suitable for use in the CAR of the present invention comprises: (a) a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1; and (b) a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
[0067] In one embodiment, the antigen binding protein suitable for use in the CAR of the present invention comprises: (a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508 and 524; (b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, NO:6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, 382, 398, 414, 430, 446, 462, 478, 494, 510 and 526; (c) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO:8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512 and 528; (d) having an amino acid sequence selected from the group consisting of SEQ ID NO:12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, a LCDR1 domain of an amino acid sequence selected from SEQ ID NO:14,30,46,62,78,94,110,126,142,158,174,190,206,230,246,262,278,294,310,326,342,358,374,390,406,422,438,454,470,486,502,518 and 534 LCDR2 domain; and (f) having an amino acid sequence selected from SEQ ID LCDR3 domains of the amino acid sequences of NO:16, 32, 48, 64, 80, 96, 112, 128, 144160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520 and 536.
[0068] In a further embodiment, the antigen binding protein suitable for use in the CAR of the present invention comprises a HCVR / LCVR amino acid sequence pair selected from SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 274, 2 42, 82 / 90, 194 / 202, 282 / 290, and 506 / 514.
[0069] In some embodiments, the isolated antigen binding protein used in the CAR of the present invention is a scFv.
[0070] In other aspects, the present invention provides vectors comprising isolated CAR nucleic acid molecules; and immune effector cells comprising such vectors.
[0071] In yet other aspects of the invention, there is provided a method for treating a subject with an HPV-related disease or condition, such as an HPV16E7-positive cancer, e.g., squamous cell carcinoma, e.g., cervical cancer, small cell carcinoma of the head and neck, anal carcinoma, and oropharyngeal cancer. The method includes administering to the subject an immune effector cell colony comprising a CAR of the present invention.
[0072] In certain aspects, the present invention provides a method for detecting, for example, HPV16E7-positive cells in a subject or in a sample obtained from a subject. The method comprises contacting a cell, for example, a cell sample obtained from a subject, with an antigen-binding protein of the present invention comprising a detectable portion, or administering an antigen-binding protein of the present invention comprising a detectable portion to a subject, and detecting the presence of the detectable portion.
[0073]
[0011] Other embodiments will become apparent upon reading the following detailed description. DETAILED DESCRIPTION
[0074] Before describing the present method, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because these methods and conditions can vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments and is not intended to limit the present invention, because the scope of the present invention is limited only by the appended claims.
[0075] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference in their entirety.
[0076] The term "human papillomavirus" ("HPV") refers to a small, non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells. The length of the circular double-stranded viral genome is about 8kb. The genome encodes 6 early proteins responsible for viral replication and 2 late proteins L1 and L2, which are viral structural proteins. More than 170 types of HPV have been identified, which are named with numbers. Certain HPV types, such as HPV-5, can establish an infection that lasts a lifetime in an individual without ever showing any clinical symptoms. HPV types 1 and 2 can cause common warts in some infected individuals. HPV types 6 and 11 can cause genital warts and respiratory papillomatosis. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 are considered to be carcinogenic.
[0077] The term "HPV16E7" refers to the HPV type 16 early gene, designated E7, and the protein translated from this gene.
[0078] The amino acid sequence of full-length HPV16E7 is provided in GenBank as accession number NP_041326.1 (SEQ ID NO: 537). The term "HPV16E7" includes recombinant HPV16E7 or fragments thereof. The term also encompasses HPV16E7 or fragments thereof coupled to, for example, a histidine tag, a mouse or human Fc, or a signal sequence (e.g., ROR1). In certain embodiments, the term includes HPV16E7 or fragments thereof in the context of HLA-A2, which are attached to HLA-A2 or displayed by HLA-A2.
[0079] The term "HLA" refers to the human leukocyte antigen (HLA) system or complex, which is a complex of genes that encodes the major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are responsible for regulating the body's immune system. HLA corresponding to MHC I classes (A, B, and C) present polypeptides from the interior of the cell.
[0080] The term "HLA-A" refers to the group of human leukocyte antigens (HLA) encoded by the HLA-A locus. HLA-A is one of the three main types of human MHC class I cell surface receptors. The receptor is a heterodimer and consists of a heavy alpha chain and a smaller beta chain. The alpha chain is encoded by the variant HLA-A gene, while the beta chain (beta2-microglobulin) is the invariant beta2 microglobulin molecule.
[0081] The term "HLA-A2" is a specific class I major histocompatibility complex (MHC) allele at the HLA-A locus. The alpha chain is encoded by the HLA-A*02 gene and the beta chain is encoded by the beta2-microglobulin or B2M locus.
[0082] As used herein, the term "antigen binding protein", "binding protein" or "binding molecule" includes molecules that contain at least one antigen binding site that specifically binds to a molecule of interest, such as a conformational epitope of an HLA-A2 presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), such as an HLA-A2 display peptide comprising amino acid residues 11-19 or 82-90. The binding protein can be an antibody, such as a full-length antibody, or an antigen-binding fragment of an antibody, or a chimeric antigen receptor (CAR), or any other polypeptide, such as a receptor-antibody (Rab) protein.
[0083] The term "HLA-A2:HPV16E7 antigen binding protein" or "HLA-A2:HPV16E7 antigen binding protein" and the like refers to an antigen binding protein, such as an antibody, or an antigen binding portion thereof, which specifically binds to a conformational epitope of a peptide fragment of HPV16E7 presented by HLA-A2, such as amino acid residues 11-19 or amino acid residues 82-90. In certain embodiments, the conformational epitope is produced on the cell surface by an HPV16E7 peptide presented by HLA-A2.
[0084] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antigen binding protein called a paratope. A single antigen may have more than one epitope. Therefore, different antigen binding proteins may bind to different regions on the antigen and may have different biological effects. The term "epitope" also refers to the site on the antigen to which B and / or T cells respond. It also refers to the region of the antigen bound by the antigen binding protein. Epitopes can be defined as structural or functional. Functional epitopes are usually a subset of structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes can also be "conformational", i.e., composed of nonlinear amino acids. In certain embodiments, an epitope may include determinants that are chemically active surface groups of a molecule, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural features and / or specific charge characteristics.
[0085] In some embodiments of the invention, the binding protein is an antibody or an antigen-binding fragment thereof, such as a full-length antibody or an antigen-binding fragment thereof.
[0086] As used herein, the term "antibody" is intended to refer to immunoglobulin molecules composed of four polypeptide chains interconnected by disulfide bonds, two heavy (H) chains and two light (L) chains (i.e., "full" antibody molecules), and multimers thereof (e.g., IgM) or antigen-binding fragments thereof. Each heavy chain comprises a heavy chain variable region ("HCVR" or "V H ”) and heavy chain constant region (including C H 1, C H 2 and C H Each light chain comprises a light chain variable region ("LCVR" or "V L ”) and the light chain constant region (C L ). You can set V H and V L The V region is further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V L It is composed of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the present invention, the FR (or antigen-binding fragment) of the antibody may be identical to the human germline sequence, or may be naturally or artificially modified. The amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0087] Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antigen binding proteins, such as antibodies, have been described in the scientific literature in which one or two CDRs can be omitted for binding. Padlan et al. (1995 FASEB J. 9: 133-139) analyzed the contact areas between an antibody and its antigen based on published crystal structures and concluded that only about 1 / 5 to 1 / 3 of the CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDRs had no amino acids that contacted the antigen (see also Vajdos et al., 2002 J Mol Biol 320: 415-428).
[0088] CDR residues that do not contact the antigen can be identified from Kabat CDR regions outside of the Chothia CDRs based on previous studies (e.g., H60-H65 residues in CDRH2 are generally not required), by molecular modeling and / or empirically. If a CDR or its residues are omitted, they are typically replaced with an amino acid occupying the corresponding position in another human antibody sequence or a consensus sequence of such sequences. The replacement position in the CDR and the amino acid to be replaced can also be selected empirically. Empirical replacements can be conservative or non-conservative replacements.
[0089] Anti-HLA-A2: HPV16E7 antigen binding proteins disclosed herein, for example, fully human anti-HLA-A2: HPV16E7 monoclonal antibodies, or antigen binding fragments thereof, or CARs, may comprise one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be easily determined by comparing the amino acid sequences disclosed herein with germline sequences that can be obtained, for example, from public antibody sequence databases. The present invention includes antigen binding proteins, such as antibodies, or CARs thereof, or antigen binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids in one or more frameworks and / or CDR regions are mutated to the corresponding residues of the germline sequence from which the antigen binding protein is derived, or mutated to the corresponding residues of another human germline sequence, or mutated to the conservative amino acid substitutions of the corresponding germline residues (such sequence changes are collectively referred to herein as "germline mutations"). One of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can readily generate numerous antigen binding proteins, such as antibodies, or antigen binding fragments thereof, or CARs, comprising one or more individual germline mutations or combinations thereof. H and / or V LAll framework and / or CDR residues in the domain are mutated back to the residues found in the original germline sequence from which the antigen-binding antibody, such as an antibody, is derived. In other embodiments, only some residues are mutated back to the original germline sequence, for example, only the mutated residues found in the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only the mutated residues found in CDR1, CDR2 or CDR3. In other embodiments, one or more framework and / or CDR residues are mutated to the corresponding residues of different germline sequences (i.e., different from the germline sequence of the germline sequence of the antibody initially derived from it). In addition, the antigen-binding proteins of the present invention, such as antibodies, or antigen-binding fragments thereof, or CAR, can include any combination of two or more germline mutations in the framework and / or CDR region, for example, wherein some individual residues are mutated to the corresponding residues of a specific germline sequence, and some other residues different from the original germline sequence are maintained or mutated to the corresponding residues of different germline sequences. Once obtained, antigen binding proteins, such as antibodies, and antigen binding fragments, which contain one or more germline mutations, can be easily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antigen binding proteins, such as antibodies, or antigen binding fragments thereof, or CARs obtained in this general manner are included in the present invention.
[0090] The present invention also includes antigen binding proteins, e.g., fully human anti-HLA-A2:HPV16E7 monoclonal antibodies, or antigen binding fragments thereof, or CARs, comprising any variant of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins having HCVR, LCVR and / or CDR amino acid sequences having, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any HCVR, LCVR and / or CDR amino acid sequences disclosed herein.
[0091] As used herein, the term "human antibody" is intended to include antibodies with variable regions and constant regions derived from human germline immunoglobulin sequences. Human monoclonal antibodies (mAbs) of the present invention may include, for example, amino acid residues not encoded by human germline immunoglobulin sequences in CDR (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). Especially CDR3. However, as used herein, the term "human antibody" is not intended to include mAbs in which the CDR sequences derived from the germline of another mammalian species (e.g., mice) are grafted onto human FR sequences. The term includes antibodies recombinantly produced in non-human mammals or non-human mammalian cells. The term is not intended to include antibodies separated or produced from human subjects.
[0092] The term "recombinant" as used herein refers to an antigen-binding protein of the invention, such as an antibody, or an antigen-binding fragment thereof, created, expressed, isolated, or obtained by techniques or methods known in the art as recombinant DNA technology, including, for example, DNA splicing and transgenic expression. The term refers to an antigen-binding protein, for example, expressed in a non-human mammal (including a transgenic non-human mammal, such as a transgenic mouse) or cell (e.g., CHO cell) expression system, or an antibody isolated from a recombinant combinatorial human antibody library.
[0093] As used herein, the terms "chimeric antigen receptor" or "CAR" are used interchangeably herein and refer to a recombinant fusion protein comprising an extracellular domain that is capable of binding to an antigen (e.g., a conformational epitope of an HPV16E7 peptide displayed by HLA-A2, such as a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7), a transmembrane domain, and at least one intracellular signaling domain.
[0094] As used herein, "immune effector cell" refers to any cell of the immune system having one or more effector functions (e.g., cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and / or CDC). In one embodiment, the immune effector cell used with CAR as described herein is a T lymphocyte, particularly a cytotoxic T cell (CTL; CD8+T cell) and a helper T cell (HTL; CD4+T cell). Other populations of T cells may also be used in this study, such as natural T cells and memory T cells. As will be appreciated by those skilled in the art, other cells may also be used as immune effector cells together with CAR as described herein. In particular, immune effector cells also include NK cells, NKT cells, neutrophils and macrophages. Immune effector cells also include progenitor cells of effector cells, wherein these progenitor cells can be induced to differentiate into immune effector cells in vivo or in vitro. Therefore, in this regard, immune effector cells include progenitor cells of immune effector cells, such as hematopoietic stem cells (HSCs) contained in a CD34+ cell population from umbilical cord blood, bone marrow or mobilized peripheral blood, which differentiate into mature immune effector cells after administration to a subject, or can be induced to differentiate into mature immune effector cells in vitro.
[0095] As disclosed herein, the term "off-target peptide" refers to a peptide that differs from a target peptide (e.g., HPV16E7 11-19 peptide) by 1, 2, 3, 4, 5 or more amino acids. In certain embodiments, the term includes peptides that differ from a target peptide by less than or equal to 3 amino acids. For example, for a 9-mer peptide, if 1, 2 or 3 amino acids are different from the target peptide, it is considered an "off-target" peptide. In certain embodiments, amino acid identity is expressed as "similarity" (DoS). If 6 or more amino acids within a 9-mer peptide are identical, the DoS is 6. In certain embodiments, peptides with DoS ≤ 6 are considered "off-target" peptides. The term "off-target" peptide also refers to a peptide that is similar to a target peptide based on sequence homology, is predicted to bind to HLA-A2, and is contained in a protein expressed in basic, normal tissues.
[0096] The term "specific binding" or "specifically binds to" and the like means that an antigen binding protein, such as an antibody, or an antigen binding fragment thereof, or CAR, forms a relatively stable complex with the antigen under physiological conditions. Specific binding can be achieved by at least about 1×10 -8 M or smaller equilibrium dissociation constant (e.g., k D The smaller the value, the tighter the binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, etc. As described herein, antigen binding proteins, such as antibodies, have been identified by surface plasmon resonance, for example, BIACORE TM, which specifically binds to a conformational epitope of HLA-A2-presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), such as a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7.
[0097] The term "high affinity" antigen binding protein, such as an antibody, refers to an antigen binding protein having at least 10 -8 M; preferably 10 -9 M; more preferably 10 -10 M, even more preferably 10 -11 M, even more preferably 10 -12 The binding affinity of an antigen binding protein, e.g., a monoclonal antibody, to a conformational epitope of an HLA-A2 presented HPV16E7 peptide, e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7, is denoted as K D , as measured by surface plasmon resonance, e.g., BIACORE TM or solution affinity ELISA.
[0098] The term "slow off rate", "Koff" or "kd" refers to the rate at which an antigen binding protein -3 s -1 or smaller, preferably 1×10 -4 s -1 or less from HLA-A2:HPV16E7 as measured by surface plasmon resonance, e.g., BIACORE TM .
[0099] As used herein, the term "antigen binding portion" of an antigen binding protein (e.g., an antibody), "antigen binding fragment" of an antigen binding protein (e.g., an antibody), and the like, includes any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the term "antigen binding fragment" of an antibody, or "antibody fragment", refers to one or more fragments of an antibody that retain the ability to bind to a conformational epitope of an HLA-A2-presented HPV16E7 peptide, for example, a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7 coupled to HLA-A2.
[0100] In a specific embodiment, an antigen binding protein of the invention, such as an antibody or antibody fragment, or CAR, can be conjugated to a moiety, such as a ligand, a detectable moiety, or a therapeutic moiety ("immunoconjugate"), such as a cytotoxin, a second anti-HLA-A2:HPV16E7 antigen binding protein, an antibody against a tumor-specific antigen, an anti-cancer drug, or any other therapeutic moiety that can be used to treat a disease or condition, including an HPV-related disease or condition, such as an HPV16E7-positive cancer or an HPV infection, including a chronic HPV infection.
[0101] As used herein, "isolated antigen binding protein", e.g., isolated antibody, is intended to refer to an antigen binding protein, e.g., an antibody, that is substantially free of other antigen binding proteins, e.g., antibodies (Abs), having different antigen specificities (e.g., an isolated antibody that specifically binds to HLA-A2:HPV16E7, or a fragment thereof, that is substantially free of antigen binding proteins, e.g., antibodies, that specifically bind to antigens other than conformational epitopes of HLA-A2 presenting HPV16E7 peptides).
[0102] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows for the detection of surface plasmon resonances by, for example, using BIACORE TM The ELISA system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ) detects changes in protein concentration within a biosensor matrix to analyze biomolecular interactions in real time.
[0103] As used herein, the term "K D ” refers to the equilibrium dissociation constant for a specific antigen binding protein-antigen interaction.
[0104] The term "cross competition" as used herein refers to an antigen binding protein, such as an antibody, or an antigen binding fragment thereof, binding to an antigen and inhibiting or blocking the binding of another antigen binding protein, such as an antibody, or an antigen binding fragment thereof. The term also includes competition between two antigen binding proteins, such as antibodies, in two directions, that is, a first antigen binding protein, such as an antibody, which binds and blocks the binding of a second antigen binding protein, such as an antibody, and vice versa. In some embodiments, a first antigen binding protein, such as an antibody, and a second antigen binding protein, such as an antibody, can bind to the same epitope. Alternatively, the first and second antigen binding proteins, such as antibodies, can bind to different, but overlapping epitopes so that the binding of one inhibits or blocks the binding of the second, for example, by steric hindrance. The cross competition between antigen binding proteins, such as antibodies, can be measured by methods known in the art, for example, by real-time, label-free biolayer interferometry. The cross competition between two antigen binding proteins, such as antibodies, can be expressed as the binding of a second antigen binding protein, such as an antibody, which is less than the background signal (wherein the first and second antigen binding proteins, such as antibodies, are the same antigen binding proteins, such as antibodies) due to self-binding. Cross-competition between two antigen binding proteins, e.g., antibodies, can be expressed, e.g., as % binding of the second antigen binding protein, e.g., antibody, which is less than baseline self-background binding (where the first and second antigen binding proteins, e.g., antibodies, are the same antigen binding protein, e.g., antibody).
[0105] The term "substantially identical" or "substantially identical" when referring to nucleic acids or fragments thereof means that when optimally aligned with another nucleic acid (or its complementary strand) with appropriate nucleotide insertions or deletions, there is at least about 90%, more preferably at least about 95%, 96%, 97%, 98% or 99% nucleotide sequence identity of the nucleotide bases, as measured by any of the well-known sequence identity algorithms discussed below. Nucleic acid molecules substantially identical to a reference nucleic acid molecule can, in some cases, encode a polypeptide having the same or substantially similar amino acid sequence as a polypeptide encoded by the reference nucleic acid molecule.
[0106] Sequence identity can be calculated using algorithms such as the Needleman Wunsch algorithm (Needleman and Wunsch 1970, J. Mol. Biol. 48: 443-453) for global alignment or the Smith Waterman algorithm (Smith and Waterman, 1981, J. Mol. Biol. 147: 195-197) for local alignment. Another preferred algorithm is described by Dufresne et al. in Nature Biotechnology (Vol. 20, pp. 1269-71) in 2002, which is used in the software GenePAST (GQ Life Sciences, Inc. Boston, MA).
[0107] When applied to polypeptides, the term "substantially similar" or "substantially similar" means that two peptide sequences share at least 90% sequence identity, even more preferably at least 95%, 96%, 97%, 98% or 99% sequence identity when optimally aligned, for example, by the GAP or BESTFIT programs using default gap weights. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is a substitution in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Typically, conservative amino acid substitutions do not substantially change the functional properties of the protein. In the case where two or more amino acid sequences differ from each other by conservative substitutions, the percentage or degree of similarity can be adjusted upward to correct for the conservative nature of the substitution. Means for making such adjustments are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference. Examples of groups of amino acids having side chains with similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxy side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid, and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al., (1992) Science 256:1443-45, incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
[0108] Sequence analysis software is usually used to measure the sequence similarity of polypeptides. Protein analysis software uses similarity metrics assigned to various displacements, deletions and other modifications (including conservative amino acid substitutions) to match similar sequences. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine the sequence homology or sequence identity between closely related polypeptides (for example, homologous polypeptides from organisms of different species or between wild-type proteins and their mutant proteins). See, for example, GCG version 6.1. FASTA with default or recommended parameters can also be used to compare polypeptide sequences; it is a program in GCG version 6.1. FASTA (such as FASTA2 and FASTA3) provides comparison and sequence identity percentage (Pearson (2000), supra) of the best overlapping region between the query sequence and the search sequence. When the sequence of the present invention is compared with a database comprising a large number of sequences from different organisms, another preferred algorithm is a computer program BLAST using default parameters, particularly BLASTP or TBLASTN. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is incorporated herein by reference.
[0109] The phrase "therapeutically effective amount" refers to an amount that produces the desired effect for which it is administered. The exact amount will depend on the purpose of the treatment and will be determined by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).
[0110] As used herein, the term "subject" refers to an animal, preferably a mammal, in need of improvement, prevention and / or treatment of a disease or condition such as HPV infection or HPV-related disease or condition, such as HPV-related cancer (e.g., HPV16E7-positive cancer). The term includes human subjects who have or are at risk of having an HPV-related disease or condition, such as an HPV-related cancer, a metastatic HPV-related cancer, or an HPV infection.
[0111] As used herein, "anticancer agent" refers to any agent that can be used to treat or improve or inhibit cancer, including but not limited to cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, cyclophosphamide, mytotane (O, P'-(DDD)), biological agents (such as antibodies and interferons) and radioactive agents. As used herein, "cytotoxin or cytotoxic agent" also refers to chemotherapeutic agents and refers to any agent that is harmful to cells. Examples include (paclitaxel), temozolomide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine (coichicin), doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin and their analogs or homologs.
[0112] As used herein, the term "antiviral drug" refers to any drug or therapy used to treat, prevent or ameliorate a viral infection in a host subject. The term "antiviral drug" includes, but is not limited to, zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine, analgesics and corticosteroids.
[0113] An immunogen comprising any of the following can be used to generate an antigen binding protein, such as an antibody, that presents a conformational epitope of an HPV16E7 peptide against HLA-A2, for example, a peptide comprising amino acid residues 11-19 or residues 82-90 of HPV16E7 linked to HLA-A2. In certain embodiments, the antigen binding protein, such as an antibody, of the invention is obtained from mice immunized with a full-length native HPV16E7 protein linked to HLA-A2 (see NCBI Accession No. NP_041326.1) (SEQ ID NO: 537), or with a recombinant HPV16E7 peptide, such as amino acid residues 11-19 (YMLDLQPET; SEQ ID NO: 538) comprising GenBank Accession No. NP_041326.1 (SEQ ID NO: 537) or amino acid residues 82-90 (LLMGTLGIV; SEQ ID NO: 539) comprising GenBank Accession No. NP_041326.1 (SEQ ID NO: 537).
[0114] Alternatively, HPV16 E7 or fragments thereof can be produced using standard biochemical techniques and modified in the context of HLA-A2 and used as immunogens.
[0115] In some embodiments, the immunogen can be a recombinant HPV 16 E7 peptide expressed in E. coli or in any other eukaryotic or mammalian cells such as Chinese Hamster Ovary (CHO) cells.
[0116] In certain embodiments, antigen binding proteins that specifically bind to conformational epitopes of HLA-A2 presenting HPV16E7 peptides can be prepared using fragments of the above regions, or peptides extending from the N or C termini or both of the regions described herein beyond the specified regions by about 5 to about 20 amino acid residues. In certain embodiments, any combination of the above regions or fragments thereof can be used to prepare HLA-A2:HPV16E7 specific antigen binding proteins, such as antibodies.
[0117] The peptides may be modified to include addition or substitution of certain residues for labeling or for conjugation to a carrier molecule such as KLH. For example, a cysteine may be added to the N-terminus or C-terminus of the peptide, or a linker sequence may be added to prepare the peptide for conjugation to KLH, for example, for immunization.
[0118] Non-limiting exemplary in vitro assays for measuring binding activity are described in the Examples herein. In Example 4, the binding affinity and kinetic constants of human anti-HLA-A2: HPV16E7 specific antigen binding proteins, such as antibodies, are determined by surface plasmon resonance, measured on a Biacore 4000 or T200 instrument. Examples 6 and 7 describe the binding of antibodies to cells overexpressing HPV16E7 fragments.
[0119] Antigen binding proteins, such as antibodies, specific for HLA-A2: HPV16E7 may not contain additional labels or moieties, or they may contain N-terminal or C-terminal tags or moieties. In one embodiment, the label or moiety is biotin. In the binding assay, the position of the label (if any) can determine the orientation of the peptide relative to the surface of the binding peptide. For example, if the surface is coated with avidin, the peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide will be at the distal end of the surface. In one embodiment, the label can be a radionuclide, a fluorescent dye or an MRI detectable label. In certain embodiments, antigen binding proteins labeled in this way can be used for diagnostic assays, including imaging assays.
[0120] Antigen Binding Protein
[0121] The present invention provides antigen binding proteins, including antibodies, or antigen binding fragments thereof, and CAR (e.g., nucleic acid molecules encoding CAR of the present invention) (described below). Unless otherwise expressly stated, the term "antibody" used herein should be understood to include antibody molecules (i.e., "complete antibody molecules") and antigen binding fragments thereof comprising two heavy immunoglobulin chains and two light immunoglobulin chains. As used herein, the term "antigen binding portion" of an antibody, "antigen binding fragment" of an antibody, etc., include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptides or glycoproteins that specifically bind to an antigen to form a complex. As used herein, the term "antigen binding fragment" or "antibody fragment" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to the conformational epitope of HLA-A2 presenting HPV16E7 peptides. Antigen binding proteins, such as antibody fragments, can include Fab fragments, F(ab')2 fragments, Fv fragments, dAb fragments, fragments containing CDRs, or separated CDRs. Antigen binding proteins, such as antigen binding fragments of antibodies, can be derived from, for example, complete antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving manipulation and expression of DNA encoding antibody variable and (optionally) constant domains. Such DNA is known and / or can be readily obtained from, for example, commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized, can be chemically or by using molecular biology techniques, DNA is sequenced and manipulated, for example, one or more variable and / or constant domains are arranged into a suitable configuration, or codons are introduced, cysteine residues are generated, amino acids are modified, added or deleted, etc.
[0122] Non-limiting examples of antigen-binding fragments of antibodies include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units, which consist of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementary determining region (CDR), such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, di-antibodies, tri-antibodies, tetra-antibodies, mini-antibodies, nano-antibodies (e.g., monovalent nano-antibodies, divalent nano-antibodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variable IgNAR domains are also included in the expression "antigen-binding fragment" as used herein.
[0123] An antigen binding fragment of an antigen binding protein (e.g., an antibody) will generally contain at least one variable domain. The variable domain can be of any size or amino acid composition and will generally contain at least one CDR adjacent to or within a framework having one or more framework sequences. L Domain-associated V H In antigen binding proteins with domains, V H and V L The domains may be arranged in any suitable arrangement relative to each other. For example, the variable region may be a dimer and contain V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a monomer V H or V L Structural domain.
[0124] In certain embodiments, the antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of an antigen-binding protein of the invention include: (i) H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H3; (xiii) V L -C H 2-C H 3; and (XIV) V L -C L . In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly connected to each other, or may be connected by all or part of a hinge or connecting region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which results in a flexible or semi-flexible connection between adjacent variable and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragments of the antibodies of the present invention may include homodimers or heterodimers (or other multimers) that have non-covalent bonds to each other and / or have one or more monomer V H or V L Any of the above listed variable and constant domain configurations of the domains (e.g., via disulfide bonds).
[0125] As with complete antibody molecules, antigen binding proteins, e.g., antigen binding fragments of antibodies, can be monospecific or multispecific (e.g., bispecific). A multispecific antigen binding fragment of an antibody will typically comprise at least two different variable domains, each of which is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Using conventional techniques available in the art, any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of an antigen binding fragment of an antibody of the invention.
[0126] Preparation of antigen binding proteins
[0127] Methods for producing antigen binding proteins such as human antibodies in transgenic mice are known in the art. Any such known methods can be used in the context of the present invention to prepare human antibodies that specifically bind to conformational epitopes of HLA-A2-presented human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide).
[0128] use Technology (see, e.g., US6,596,541, Regeneron Pharmaceuticals, ) or any other known method for producing antigen binding proteins, e.g., monoclonal antibodies, high affinity antigen binding proteins for HLA-A2 presenting conformational epitopes of HPV16E7 peptides, e.g., chimeric antibodies, are initially isolated as having human variable regions and mouse constant regions. VELOCIMMUNE technology involves generating transgenic mice having a genome comprising human heavy and light chain variable regions operably linked to endogenous mouse constant region loci, such that the mice produce antigen binding proteins, e.g., antibodies, comprising human variable regions and mouse constant regions in response to antigenic stimulation. DNA encoding the variable regions of the heavy and light chains of the antibodies is separated and operably linked to DNA encoding human heavy and light chain constant regions. The DNA is then expressed in cells capable of expressing fully human antibodies.
[0129] Typically, challenge with the antigen of interest Mouse, lymphocytes (such as B cells) are recovered from mice expressing antigen-binding proteins, such as antibodies. Lymphocytes can be fused with myeloma cell lines to prepare immortalized hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to target antigens. The DNA encoding the heavy chain and light chain variable regions can be separated and connected to the desired isotype constant regions of the heavy chain and light chain. Such antigen-binding proteins can be produced in cells, such as CHO cells. Alternatively, the DNA encoding antigen-specific antigen-binding proteins, such as chimeric antibodies, or the variable domains of light and heavy chains can be directly separated from antigen-specific lymphocytes.
[0130] First, high-affinity antigen-binding proteins, for example, chimeric antibodies, are separated into people's variable regions and mouse constant regions. As in the experimental section below, antigen-binding proteins are characterized by desired properties and are selected for desired properties, including affinity, selectivity, epitopes, etc. The mouse constant region is replaced by the desired human constant region to generate antigen-binding proteins of the present invention, for example, fully human antibodies, such as wild-type or modified IgG1 or IgG4. Although the constant region selected can vary according to specific use, high-affinity antigen binding and target-specific characteristics are present in the variable region.
[0131] Bioequivalent
[0132] The anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention encompass amino acid sequences that vary from those described antigen binding proteins, such as antibodies, but retain the ability to bind to HLA-A2 presenting conformational epitopes of HPV16E7 peptides. Such variant antigen binding proteins contain one or more additions, deletions or substitutions of amino acids when compared to the parent sequence, but exhibit biological activity substantially equivalent to the described antigen binding proteins. Similarly, the antigen binding protein encoding DNA sequences of the present invention encompass sequences that contain one or more additions, deletions or substitutions of nucleotides when compared to the disclosed sequences, but encode antigen binding proteins that are substantially biologically equivalent to the antigen binding proteins of the present invention.
[0133] If, for example, two antigen binding proteins or antibodies are pharmaceutical equivalents or drug substitutes whose absorption rate and extent do not show significant differences when administered at the same molar dose under similar experimental conditions, whether single or multiple doses, they are considered bioequivalent. If some antigen binding proteins or antibodies are equivalent in their extent of absorption but not their absorption rate, they will be considered equivalents or drug substitutes, and because such absorption rate differences are intentional and reflected in the labeling, are not essential to obtain effective in vivo drug concentrations (e.g., long-term use), and are considered medically insignificant for the specific drug under study, they are considered bioequivalent.
[0134] In one embodiment, two antigen binding proteins (or antibodies) are bioequivalent if there are no clinically meaningful differences in their safety, purity, or potency.
[0135] In one embodiment, two antigen binding proteins (or antibodies) are bioequivalent if a patient can switch one or more times between the reference product and the biological product without an expected increase in risk of adverse reactions, including clinically significant changes in immunogenicity, or reduced effectiveness, compared to continued treatment without such a switch.
[0136] In one embodiment, two antigen binding proteins (or antibodies) are bioequivalent if they both act by one or more common mechanisms of action for one or more instances of use to the extent that these mechanisms are known.
[0137] Bioequivalence can be demonstrated by in vivo and / or in vitro methods. Bioequivalence measures include, for example, (a) in vivo tests in humans or other mammals, where the concentration of the antigen binding protein or its metabolites is measured in blood, plasma, serum or other biological fluids as a function of time; (b) in vitro tests that have been correlated with human in vivo bioavailability data and can be reasonably predicted; (c) in vivo tests in humans or other mammals, where the appropriate acute pharmacological effects of the antigen binding protein (or its target) are measured as a function of time; and (d) in well-controlled clinical trials, which determine the safety, efficacy, or bioavailability or bioequivalence of the antigen binding protein.
[0138] Bioequivalent variants of the antigen-binding proteins (or antibodies) of the present invention can be constructed by, for example, performing various substitutions of residues or sequences or deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine residues that are not essential for biological activity can be deleted or replaced by other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bonds during renaturation. In other cases, bioequivalent antigen-binding proteins can include antigen-binding protein variants comprising amino acid changes that change the glycosylation characteristics of the antigen-binding protein, for example, mutations that eliminate or remove glycosylation.
[0139] Anti-HLA-A2:HPV16E7 antigen binding proteins including Fc variants
[0140] According to certain embodiments of the present invention, an anti-HLA-A2:HPV16E7 antigen binding protein, such as an antibody, is provided, which comprises an Fc domain, which comprises one or more mutations that enhance or attenuate the binding of the antigen binding protein to an FcRn receptor, such as at an acidic pH compared to a neutral pH. For example, the present invention includes an anti-HLA-A2:HPV16E7 antigen binding protein comprising a C in the Fc domain. H 2 or C HA mutation in region 3, wherein the mutation increases the affinity of the Fc domain for FcRn in an acidic environment (e.g., in an endosome at a pH of about 5.5 to about 6.0). Such a mutation can result in an increase in the serum half-life of the antigen binding protein when administered to an animal. Non-limiting examples of such Fc modifications include, e.g., modifications at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T) and 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., A, W, H, F or Y [N434A, N434W, N434H, N434F or N434Y]); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modification includes 428L (e.g., M428L) and 434S (e.g., N434S) modification; 428L, 259I (e.g., V259I) and 308F (e.g., V308F) modification; 433K (e.g., H433K) and 434 (e.g., 434Y) modification; 252, 254 and 256 (e.g., 252Y, 254T and 256E) modification; 250Q and 428L modification (e.g., T250Q and M428L); and 307 and / or 308 modification (e.g., 308F or 308P). In another embodiment, the modification includes 265A (e.g., D265A) and / or 297A (e.g., N297A) modification.
[0141] For example, the present invention includes an anti-HLA-A2:HPV16E7 antigen binding protein comprising an Fc domain comprising one or more mutation pairs or groups selected from the following: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N43 4S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A and 434A (e.g., T307A, E380A and N434A); and 433K and 434F (e.g., H433K and N434F). In one embodiment, the present invention includes an anti-HLA-A2: HPV16E7 antigen binding protein comprising an Fc domain comprising a mutation S108P in the IgG4 hinge region that promotes dimer stabilization. All possible combinations of the aforementioned Fc domain mutations, as well as other mutations within the variable domains of the antigen binding proteins disclosed herein, are contemplated within the scope of the present invention.
[0142] The present invention also includes an anti-HLA-A2:HPV16E7 antigen binding protein comprising a chimeric heavy chain constant (C H ) region, wherein the chimeric C H The region comprises C sequences derived from more than one immunoglobulin isotype. H For example, the antigen-binding protein of the present invention may comprise a chimeric C H A region comprising part or all of a C region derived from a human IgG1, human IgG2 or human IgG4 molecule H 2 domains, and a portion or all of the C domains derived from human IgG1, human IgG2 or human IgG4 molecules H According to certain embodiments, the antigen binding protein of the present invention comprises a chimeric C H Region, which has a chimeric hinge region. For example, the chimeric hinge may comprise an "upper hinge" amino acid sequence derived from a human IgG1, human IgG2 or human IgG4 hinge region (amino acid residues from positions 216 to 227 according to EU numbering), combined with a "lower hinge" sequence derived from a human IgG1, human IgG2 or human IgG4 hinge region (amino acid residues from positions 228 to 236 according to EU numbering). According to certain embodiments, the chimeric hinge region comprises amino acid residues derived from the upper hinge of human IgG1 or human IgG4 and amino acid residues derived from the lower hinge of human IgG2. A chimeric hinge region comprising a chimeric C as described herein HThe antigen binding proteins of the region may, in certain embodiments, exhibit altered Fc effector functions without adversely affecting the therapeutic or pharmacokinetic properties of the antigen binding protein. (See, e.g., U.S. Patent Publication No. 20140243504, the disclosure of which is incorporated herein by reference in its entirety).
[0143] Biological properties of antigen binding proteins
[0144] In general, the antigen binding proteins of the present invention function by binding to a conformational epitope of the HLA-A2-presented human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide).
[0145] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind to HPV16E7 peptides with high specificity in the context of HLA-A2. In the absence of HLA-A2, the anti-HLA-A2:HPV16E7 antigen binding proteins do not bind to HPV16E7 peptides. In addition, in the context of HLA-A2, the anti-HLA-A2:HPV16E7 antigen binding proteins do not bind to off-target peptides.
[0146] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind to monomeric HLA-A2:HPV16E711-19 peptides with high affinity. For example, the present invention includes antigen binding proteins that bind to monomeric HLA-A2:HPV16E711-19 peptides with a K of less than about 20 nM. D Binding to monomeric HLA-A2:HPV16E711-19 peptide (e.g., at 25°C or at 37°C) as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 4 herein. In certain embodiments, the antigen binding protein binds to a monomeric HLA-A2:HPV16E711-19 peptide with a K of less than about 15 nM, less than about 12 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.1 nM, less than about 0.05 nM or less than about 0.04 nM. D Binding to monomeric HLA-A2:HPV16E711-19 peptide as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 4 herein, or a substantially similar assay.
[0147] The present invention includes antigen binding proteins that have a K of less than about 25 nM. DBinding to monomeric HLA-A2:HPV16E782-90 peptide (e.g., at 25°C or at 37°C) as measured by surface plasmon resonance, e.g., using an assay format defined in Example 4 herein, or a substantially similar assay. In certain embodiments, the antigen binding protein binds to a monomeric HLA-A2:HPV16E782-90 peptide with a K of less than about 20 nM, less than about 15 nM, less than about 12 nM, less than about 10 nM, less than or equal to about 5 nM, less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.1 nM, less than about 0.05 nM or less than about 0.04 nM. D Binding to monomeric HLA-A2:HPV16E7 82-90 peptide as measured by surface plasmon resonance, eg using an assay format as defined in Example 4 herein, or a substantially similar assay.
[0148] The present invention also includes antigen binding proteins that have an EC of less than about 6 nM. 50 Binds to cells expressing the HLA-A2: HPV16E7 11-19 peptide, and does not bind to cells expressing a predicted off-target peptide, as determined by a luminescence assay, as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antigen binding protein has an EC of less than about 6 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM. 50 Binds to cells expressing the HLA-A2:HPV16E7 11-19 peptide, and does not bind to cells expressing a predicted off-target peptide, as determined by a luminescence assay, as defined in Example 6 herein, or a substantially similar assay, e.g., using the assay format in Example 6 herein, or a substantially similar assay.
[0149] The present invention also includes antigen binding proteins that have an EC of less than about 1 nM. 50 Binds to cells expressing the HLA-A2: HPV16E7 82-90 peptide, and does not bind to cells expressing a predicted off-target peptide, as determined by a luminescence assay, as defined in Example 6 herein, or a substantially similar assay. In certain embodiments, the antigen binding protein has an EC of less than about 1 nM, less than about 0.5 nM, less than about 0.2 nM, or less than about 0.01 nM. 50 Binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide, and does not bind to cells expressing a predicted off-target peptide, as determined by a luminescence assay, as defined in Example 6 herein, or a substantially similar assay, e.g., using the assay format in Example 6 herein, or a substantially similar assay.
[0150] The present invention also includes antigen binding proteins that have an EC of less than about 30 nM. 50Binding to cells expressing HLA-A2: HPV16 E782-90 peptide as measured by a flow cytometry assay, as defined in Example 7 herein, or a substantially similar assay. In certain embodiments, the antigen binding protein has an EC of less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM. 50 Binding to cells expressing the HLA-A2:HPV16E782-90 peptide as measured by a flow cytometry assay, e.g., using the assay format of Example 7 herein, or a substantially similar assay.
[0151] The present invention also includes antigen binding proteins that have an EC of less than about 75 nM. 50 Binding to cells expressing HLA-A2: HPV16 E782-90 peptide as measured by a flow cytometry assay, as defined in Example 7 herein, or a substantially similar assay. In certain embodiments, the antigen binding protein has an EC of less than about 75 nM, less than about 70 nM, less than about 65 nM, less than about 60 nM, less than about 55 nM, less than about 50 nM, less than about 45 nM, less than about 40 nM, less than about 35 nM, less than about 30 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM. 50 Binding to cells expressing the HLA-A2:HPV16E782-90 peptide as measured by a flow cytometry assay, e.g., using the assay format of Example 7 herein, or a substantially similar assay.
[0152] In certain embodiments, the antigen-binding proteins of the present invention can be used to inhibit tumor growth or delay cancer development when prophylactically administered to a subject in need, and can increase the survival of the subject. For example, administration of the antigen-binding proteins of the present invention can result in the shrinkage of primary tumors, and can prevent the metastasis or development of secondary tumors. In certain embodiments, the antigen-binding proteins of the present invention can be used to inhibit tumor growth when therapeutically administered to a subject in need, and can increase the survival of the subject. For example, administration of a therapeutically effective amount of the antigen-binding proteins of the present invention to a subject can result in the shrinkage and disappearance of established tumors in the subject.
[0153] In one embodiment, the present invention provides an isolated recombinant antigen binding protein that binds to a conformational epitope of an HLA-A2 presented HPV16E7 peptide, wherein the antigen binding protein exhibits one or more of the following features: (i) comprising a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 378, 394, 410, 426, 442, 458, 474, 490, 506 and 522, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity; (ii) comprising a HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: NO:10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 226, 242, 258, 274, 290, 306, 322, 338, 354, 370, 386, 402, 418, 434, 450, 466, 482, 498, 514 and 530, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity; (iii) comprising a sequence selected from the group consisting of SEQ ID NO:8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512 and 528, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity; and a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID 144160,176,192,208,232,248,264,280,296,312,328,344,360,376,392,408,424,440,456,472,488,504,520 and 536 amino acid sequence, or a LCDR3 domain of a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereto;(iv) comprising a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508 and 524, or a substantially similar sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereof; NO:12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516 and 532, or a LCDR1 domain having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity thereof; and a sequence selected from SEQ ID NO:14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518 and 534, or a LCDR2 domain having a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity; (v) having an association dissociation equilibrium constant (K) of less than about 20 nM; D ) binds to monomeric HLA-A2:HPV16E711-19 peptide as measured by surface plasmon resonance assay at 25°C; (vi) has a binding dissociation equilibrium constant (K) of less than about 25 nM D ) binds to monomeric HLA-A2:HPV16E782-90 peptide as measured by surface plasmon resonance assay at 25°C; (vii) binds to monomeric HLA-A2:HPV16E782-90 peptide with an EC of less than about 6 nM 50 binds to HLA-A2:HPV16E711-19 peptide-expressing cells and does not bind to cells expressing predicted off-target peptides as determined by luminescence assay; (viii) has an EC of less than about 1 nM 50 binds to HLA-A2:HPV16E711-19 peptide-expressing cells and does not substantially bind to cells expressing predicted off-target peptides as determined by luminescence assay; (ix) has an EC of less than about 30 nM50 Binds to cells expressing the HLA-A2:HPV16E711-19 peptide as determined by flow cytometry; (x) with an EC of less than about 75 nM 50 (xi) does not bind to off-target peptides displayed by HLA-A2, wherein the peptide differs from SEQ ID NO:538 by 1, 2, 3, 4, 5 or more amino acids; (xii) does not bind to off-target peptides displayed by HLA-A2, wherein the peptide differs from SEQ ID NO:539 by 1, 2, 3, 4, 5 or more amino acids.
[0154] The antigen binding proteins of the present invention may have one or more of the above biological properties, or any combination thereof. Other biological properties of the antigen binding proteins of the present invention will be apparent to those of ordinary skill in the art from this disclosure including the working examples herein.
[0155] Epitope mapping and related technologies
[0156] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that interact with one or more amino acids found within one or more domains of the HLA-A2 displaying HPV16E7 peptide. The epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) located within one or both of the aforementioned domains of the HPV16E7 molecule (e.g., a conformational epitope).
[0157] Various techniques known to those of ordinary skill in the art can be used to determine whether an antigen binding protein "interacts with" "one or more amino acids" within a polypeptide or protein. Exemplary techniques include, for example, conventional cross-blocking assays, such as described in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, New York). Other methods include alanine scanning mutation analysis, peptide blot analysis (Reineke (2004) Methods Mol. Biol. 248: 443-63), peptide cleavage analysis crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens (Tomer (2000) Prot. Sci. 9: 487-496) can be used. Another method that can be used to identify amino acids within a polypeptide with which an antigen binding protein interacts is hydrogen / deuterium exchange detected by mass spectrometry. In general, the hydrogen / deuterium exchange method involves deuterium labeling of the protein of interest, followed by binding of the antigen binding protein to the deuterium labeled protein. Next, the protein / antigen binding protein complex is transferred to water, and the exchangeable protons in the amino acids protected by the antigen binding protein complex undergo deuterium-hydrogen back exchange at a slower rate than the exchangeable protons in the amino acids that are not part of the surface. As a result, the amino acids that form part of the protein / antigen binding protein interface can retain deuterium and therefore exhibit a relatively higher mass than amino acids that are not included in the interface. After the antigen binding protein dissociates, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing deuterium-labeled residues that correspond to the specific amino acids with which the antigen binding protein interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267: 252-259; Engen and Smith (2001) Anal. Chem. 73: 256A-265A.
[0158] The term "epitope" refers to a site on an antigen to which B and / or T cells respond. B cell epitopes can be formed by both contiguous or non-contiguous amino acids juxtaposed by the tertiary folding of a protein. Epitopes formed by contiguous amino acids are usually retained when exposed to denaturing solvents, while epitopes formed by tertiary folding are usually lost when treated with denaturing solvents. An epitope usually comprises at least 3, more usually at least 5 or 8-10 amino acids in a unique spatial conformation.
[0159] Modification-Assisted Profiling (MAP), also known as Antigen Structure-based Antibody Profiling (ASAP), is a method for classifying a large number of monoclonal antigen-binding proteins, such as antibodies (mAbs), against the same antigen based on the similarity of the binding profile of each antibody to a chemically or enzymatically modified antigen surface (see US2004 / 0101920, incorporated herein by reference in its entirety). Each class can reflect a unique epitope that is significantly different from or partially overlaps with an epitope represented by another class. The technique allows rapid filtering of genetically identical antigen-binding proteins so that characterization can be focused on genetically different antigen-binding proteins. When applied to hybridoma screening, MAP can facilitate the identification of rare hybridoma clones that produce antigen-binding proteins with desired properties. MAP can be used to classify the antigen-binding proteins of the present invention into groups of antigen-binding proteins that bind to different epitopes.
[0160] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind to the same epitope, or a portion of the epitope, as any of the specific exemplary antigen binding proteins described herein in Table 1, or antigen binding proteins having the CDR sequences of any of the exemplary antigen binding proteins described in Table 1. Likewise, the present invention also includes anti-HLA-A2:HPV16E7 antigen binding proteins that compete with any of the specific exemplary antigen binding proteins described herein in Table 1, or antigen binding proteins having the CDR sequences of any of the exemplary antigen binding proteins described in Table 1 for binding to HLA-A2:HPV16E7 or a fragment thereof.
[0161] By using conventional methods known in the art, it can be easily determined whether the antigen binding protein binds to the same epitope as the reference anti-HLA-A2: HPV16E7 antigen binding protein, or competes with the reference anti-HLA-A2: HPV16E7 antigen binding protein for binding. For example, to determine whether the test antigen binding protein binds to the same epitope as the reference anti-HLA-A2: HPV16E7 antigen binding protein of the present invention, the reference antigen binding protein is allowed to bind to the HLA-A2: HPV16E7 protein or peptide under saturation conditions. Next, the ability of the test antigen binding protein to bind to the HLA-A2: HPV16E7 molecule is evaluated. If the test antigen binding protein is able to bind to HLA-A2: HPV16E7 after saturation binding with the reference anti-HLA-A2: HPV16E7 antigen binding protein, it can be concluded that the test antigen binding protein binds to an epitope different from the reference anti-HLA-A2: HPV16E7 antigen binding protein. On the other hand, if the test antigen binding protein cannot bind to the HLA-A2:HPV16E7 protein after saturation binding with the reference anti-HLA-A2:HPV16E7 antigen binding protein, the test antigen binding protein can bind to the same epitope as the epitope bound by the reference anti-HLA-A2:HPV16E7 antigen binding protein of the present invention.
[0162] To determine whether an antigen binding protein competes with a reference anti-HLA-A2:HPV16E7 antigen binding protein for binding, the above binding method is performed in two directions: In the first direction, the reference antigen binding protein is allowed to bind to the HLA-A2:HPV16E7 protein under saturating conditions, and then the binding of the test antigen binding protein to the HLA-A2:HPV16E7 molecule is evaluated. In the second direction, the test antigen binding protein is allowed to bind to the HLA-A2HPV16E7 molecule under saturating conditions, and then the binding of the reference antigen binding protein to the HLA-A2:HPV16E7 molecule is evaluated. If, in both directions, only the first (saturated) antigen binding protein is able to bind to the HLA-A2:HPV16E7 molecule, it can be concluded that the test antigen binding protein competes with the reference antigen binding protein for binding to HLA-A2:HPV16E7. As will be appreciated by one of ordinary skill in the art, an antigen binding protein that competes for binding with a reference antigen binding protein may not necessarily bind to the same epitope as the reference antigen binding protein, but may sterically block binding of the reference antigen binding protein by binding to an overlapping or adjacent epitope.
[0163] If each competitively inhibits (blocks) the binding of the other to the antigen, then the two antigen binding proteins bind to the same or overlapping epitopes. That is, a 1-, 5-, 10-, 20- or 100-fold excess of one antigen binding protein inhibits at least 50% of the binding of the other, but preferably 75%, 90% or even 99%, as measured by a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990 50: 1495-1502). Alternatively, if substantially all amino acid mutations in the antigen that reduce or eliminate the binding of one antigen binding protein reduce or eliminate the binding of the other, then the two antigen binding proteins have the same epitope. If some amino acid mutations that reduce or eliminate the binding of one antigen binding protein reduce or eliminate the binding of the other, then the two antigen binding proteins have overlapping epitopes.
[0164] Additional routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed lack of binding of the test antigen binding protein is actually due to binding to the same epitope as the reference antigen binding protein, or whether steric blocking (or other phenomena) is causing the lack of observed binding. Such experiments can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antigen binding protein binding assay available in the art.
[0165] Immunoconjugates
[0166] The present invention includes anti-HLA-A2: HPV16E7 antigen binding proteins conjugated to therapeutic moieties ("immunoconjugates"), such as cytotoxins or chemotherapeutic agents, to treat cancer. As used herein, the term "immunoconjugate" refers to an antigen binding protein that is chemically or biologically linked to a cytotoxin, a radioactive agent, a cytokine, an interferon, a target or a reporter molecule portion, such as a detectable portion, an enzyme, a toxin, a peptide or a protein or a therapeutic agent. The antigen binding protein can be linked to a cytotoxin, a radioactive agent, a cytokine, an interferon, a target or a reporter molecule portion, an enzyme, a toxin, a peptide or a therapeutic agent at any position along the molecule, as long as it is able to bind to its target. Examples of immunoconjugates include antigen binding protein-drug conjugates and antigen binding protein-toxin fusion proteins. In one embodiment, the reagent can be a second different antibody for HPV16E7 or HLA-A2: HPV16E7. In certain embodiments, the antigen binding protein can be conjugated to a reagent specific for tumor cells or virus-infected cells, i.e., HPV-infected cells. The type of therapeutic moiety that can be conjugated to the anti-HLA-A2:HPV16E7 antigen binding protein will take into account the condition to be treated and the desired therapeutic effect to be achieved. Examples of suitable reagents for forming immunoconjugates are known in the art; see, e.g., PCT Publication No. WO05 / 103081.
[0167] Chimeric Antigen Receptor (CAR)
[0168] Chimeric antigen receptors (CARs) redirect T cells specifically to antibody-recognized antigens expressed on the surface of cancer cells, while T cell receptors (TCRs) expand the target range to include intracellular tumor antigens. CARs that redirect T cells specific to the B cell differentiation antigen CD19 have shown significant efficacy in treating B cell malignancies, while TCR redirected T cells have shown benefits in patients with solid cancers. Stauss et al. describe strategies for modifying therapeutic CARs and TCRs for the treatment of cancer, such as to enhance antigen-specific effector functions and limit the toxicity of engineered T cells (Current Opinion in Pharmacology 2015, 24: 113-118).
[0169] One aspect of the present invention includes a chimeric antigen receptor (CAR) that is specific for HPV16E7 peptides displayed on the surface of tumor cells through HLA-A2, such as peptides containing amino acid residues 11-19 or 82-90 of HPV16E7. In one embodiment of the present invention, the CAR described herein comprises an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (e.g., a signaling domain derived from CD3ζ or FcRγ) and / or one or more β-stimulatory signaling domains derived from co-stimulatory molecules, such as but not limited to CD28, CD137, CD134 or CD278. In one embodiment, CAR includes a hinge or spacer between the extracellular binding domain and the transmembrane domain, such as a CD8α hinge. In another embodiment of the present invention, the CAR as described herein comprises an extracellular target-specific binding domain and a T cell receptor constant domain ("T body construct").
[0170] It will be appreciated that for any of the CARs described herein, the extracellular target-specific binding domain may comprise a Fab, Fab', (Fab')2, Fv or single-chain Fv (scFv) of an antigen binding protein of the invention.
[0171] As used herein, the binding domain or extracellular domain of CAR provides the ability to bind to a target antigen of interest to CAR. The binding domain can be any protein, polypeptide, oligopeptide or peptide with the ability to specifically recognize and bind to a biomolecule (such as a cell surface receptor or a tumor protein or its components). The binding domain includes any naturally occurring, synthetic, semi-synthetic or recombinantly produced binding partner of the biomolecule of interest. For example, and as further described herein, the binding domain can be the light chain and heavy chain variable region of an antibody, or the light chain and heavy chain variable region can be connected together in a single chain and in either direction (e.g., VL-VH or VH-VL). A variety of assays for identifying the binding domain of the present disclosure specifically bound to a specific target are known, including Western blotting, ELISA, flow cytometry or surface plasmon resonance analysis (e.g., using BIACORE analysis), and are described herein. The target can be any clinically interesting antigen that is expected to trigger an effector immune response that causes tumor killing. In one embodiment, the target antigen of the binding domain of the chimeric antigen receptor is a conformational epitope of an HPV16E7 peptide presented by HLA-A2 on the surface of a tumor cell, such as a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7.
[0172] Schematic binding domains include antigen binding proteins, such as antigen binding fragments of antibodies, such as scFv, scTCR, extracellular domains of receptors, ligands for cell surface molecules / receptors, or receptor binding domains thereof, and tumor binding proteins. In certain embodiments, the antigen binding domains included in the CAR of the present invention can be variable regions (Fv), CDR, Fab, scFv, VH, VL, domain antibody variants (DAB), camel antibodies (VHH), fibronectin 3 domain variants, ankyrin repeat variants, and other antigen-specific binding domains derived from other protein scaffolds.
[0173] In one embodiment, the binding domain of CAR is an anti-HLA-A2: HPV16E7 single-chain antibody (scFv), and can be a mouse, human or humanized scFv. Single-chain antibodies can be cloned from the V region genes of hybridomas specific for the desired target. Techniques that can be used to clone variable region heavy chains (VH) and variable region light chains (VL) have been described, for example, in Orlandi et al., PNAS, 1989; 86: 3833-3837. Therefore, in certain embodiments, the binding domain comprises an antibody-derived binding domain, but can be a non-antibody-derived binding domain. The antibody-derived binding domain can be a fragment of an antibody or a genetically engineered product of one or more fragments of an antibody, which fragment is involved in binding to an antigen.
[0174] In certain embodiments, the CAR of the present invention may include a joint between each domain, which is added for proper spacing and conformation. For example, in one embodiment, there may be a joint between the binding domains VH or VL, and its length may be between 1-10 amino acids. In other embodiments, the joint between any domains of the chimeric antigen receptor may be 1-20 or 20 amino acids long. In this regard, the joint may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids long. In a further embodiment, the joint may be 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids long. The range including the numbers described herein is also included herein, such as a joint with a length of 10-30 amino acids.
[0175] In certain embodiments, the joint suitable for CAR described herein is a flexible joint. Suitable joints can be easily selected, and can have any suitable different lengths, such as 1 amino acid (e.g., Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, can be 1,2,3,4,5,6 or 7 amino acids.
[0176] Exemplary flexible linkers include glycine polymers (G) n, glycine-serine polymers, wherein n is an integer of at least one, glycine-alanine polymers, alanine-serine polymers and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively structureless and can therefore be used as neutral tethers between domains of fusion proteins (e.g., CAR described herein). Glycine reaches significantly more phi-psi space than even alanine, and is much less restricted than residues with longer side chains (see Scheraga, Rve. Computational Chem. 11173-142 (1992)). It will be appreciated by those of ordinary skill in the art that the design of CAR may include all or part of a flexible linker, so that the linker may include a flexible linker and one or more portions that impart a less flexible structure to provide the desired CAR structure.
[0177] The CAR binding domain may be followed by a "spacer" or "hinge", which refers to a region where the antigen binding domain is moved away from the effector cell surface to enable appropriate cell / cell contact, antigen binding and activation (Patel et al., Gene Therapy, 1999; 6: 412-419). The hinge region in CAR is typically between the transmembrane (TM) and the binding domain. In certain embodiments, the hinge region is an immunoglobulin hinge region, and may be a wild-type immunoglobulin hinge region or an altered wild-type immunoglobulin hinge region. Other exemplary hinge regions used in the CAR described herein include hinge regions derived from the extracellular region of type 1 membrane proteins, such as CD8α, CD4, CD28, and CD7, which may be wild-type hinge regions from these molecules or may be altered. In one embodiment, the hinge region includes a CD8α hinge.
[0178] The "transmembrane" region or domain is a part of CAR that anchors the extracellular binding portion to the plasma membrane of immune effector cells and promotes the binding of the binding domain to the target antigen. The transmembrane domain can be a CD3ζ transmembrane domain, but other transmembrane domains that can be used include those obtained from CD8α, CD4, CD28, CD45, CD9, CD16, CD22, CD33, CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain is the transmembrane domain of CD137. In some embodiments, the transmembrane domain is synthetic, in which case it will mainly contain hydrophobic residues, such as leucine and valine.
[0179] "Intracellular signaling domain" refers to a part of a chimeric antigen receptor protein that is involved in transducing information of an effective CAR bound to a target antigen to the interior of an immune effector cell to elicit effector cell functions, e.g., activation, cytokine production, proliferation, and cytotoxic activity, including the release of cytotoxic factors to CAR-bound target cells, or other cellular responses caused by the binding of antigens to the extracellular CAR domain. The term "effector function" refers to a specialized function of a cell. The effector function of a T cell may be, for example, cytolytic activity or help or activity including cytokine secretion. Therefore, the term "intracellular signaling domain" refers to a part of a protein that transduces effector function signals and directs cells to perform specialized functions. Although the entire intracellular signaling domain can generally be used, in many cases, the entire domain does not have to be used. In terms of using a truncated portion of an intracellular signaling domain, as long as it transduces an effector function signal, the truncated portion can be used instead of the entire domain. The term intracellular signaling domain is intended to include any truncated portion of an intracellular signaling domain sufficient to transduce an effector function signal. The intracellular signaling domain is also referred to as a "signaling domain" and is typically derived from a portion of the human CD3 or FcRy chain.
[0180] It is known that the signal generated by the T cell receptor alone is not enough to fully activate T cells, and secondary or co-stimulatory signals are also required. Therefore, it can be said that T cell activation is mediated by two different types of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the T cell receptor (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide secondary or co-stimulatory signals (secondary cytoplasmic signaling sequences). The primary cytoplasmic signaling sequence regulates the primary activation of the T cell receptor complex in an inhibitory or inhibitory manner. The primary cytoplasmic signaling sequence that acts in a co-stimulatory manner can contain a signal motif, which is called an immunoreceptor tyrosine-based activation motif or ITAM.
[0181] Examples of primary cytoplasmic signaling sequences containing ITAMs that are particularly useful in the present invention include those derived from TCRζ, FcRγ, FcRβ, CD3γ, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In certain specific embodiments, the intracellular signaling domain of the anti-HLA-A2:HPV16E7 CAR described herein is derived from CD3ζ or FcRγ.
[0182] As used herein, the term "costimulatory signaling domain" or "costimulatory domain" refers to the portion of the intracellular domain of the CAR containing costimulatory molecules. Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors, which provide secondary signals required for effective activation of T lymphocytes and functions after binding to antigens. Examples of such costimulatory molecules include CD27, CD28, 4-1BB (CD137), OX40 (CD134), CD30, CD40, PD-1, ICOS (CD278), LFA-1, CD2, CD7, LIGHT, NKD2C, B7-H2, and ligands that specifically bind to CD83. Therefore, although the present disclosure provides exemplary costimulatory domains derived from CD3ζ and 4-1BB, other costimulatory domains are also considered for use with CAR described herein. The inclusion of one or more costimulatory signaling domains can enhance the efficacy and amplification of T cells expressing CAR receptors. The intracellular signaling and co-stimulatory signaling domains can be linked in tandem in any order to the carboxyl terminus of the transmembrane domain.
[0183] Although scFv-based CARs engineered to contain signaling domains from CD3 or FcRγ have been shown to deliver effective signals for T cell activation and effector function, they are insufficient to elicit signals that promote T cell survival and expansion without accompanying co-stimulatory signals. Other CARs that contain binding domains, hinges, transmembrane and signaling domains derived from CD3ζ or FcRγ together with one or more co-stimulatory signaling domains (e.g., intracellular co-stimulatory domains derived from CD28, CD137, CD134 and CD278) can more effectively direct anti-tumor activity in animal models and in cancer patients, as well as increased cytokine secretion, lytic activity, survival and proliferation of CAR-expressing T cells in vitro (Milone et al., Molecular Therapy, 2009; 17: 1453-1464; Zhong et al., Molecular Therapy, 2010; 18: 413-420; Carpenito et al., PNAS, 2009; 106: 3360-3365).
[0184] In one embodiment, the HLA-A2: HPV16E7 CAR of the present invention comprises (a) an anti-HLA-A2: HPV16E7 scFv as a binding domain (e.g., an scFv having a binding region (e.g., CDR or variable domain) from one or more of the HLA-A2: HPV16E7 antibodies described in Table 1), (b) a hinge region derived from human CD8α, (c) a human CD8α transmembrane domain, and (d) a human T cell receptor CD3ζ chain (CD3) intracellular signaling domain, and optionally, one or more costimulatory signaling domains derived from CD28, CD137, CD134, and CD278. In one embodiment, the different protein domains are arranged in the following order from amino to carboxyl terminus: a binding domain, a hinge region, and a transmembrane domain. The intracellular signaling domain and the optional costimulatory signaling domain are tandemly connected to the transmembrane carboxyl terminus in any order to form a single-chain chimeric polypeptide. In one embodiment, the nucleic acid construct encoding HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, for example, human anti-HLA-A2:HPV16E7 scFv, human CD8α hinge, human CD8α transmembrane domain and CD3ζ intracellular signaling domain (5' to 3') coding sequence. In another embodiment, the nucleic acid construct encoding HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, for example, human anti-HLA-A2:HPV16E7 scFv, human CD8α hinge, human CD8α transmembrane domain, CD137 costimulatory domain and CD3ζ costimulatory domain (5' to 3') coding sequence. In certain embodiments, the nucleic acid construct encoding the HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, such as a human anti-HLA-A2:HPV16E7 scFv, a human CD8α hinge, a human CD8α transmembrane domain, a CD137 co-stimulatory domain, and a CD3ζ co-stimulatory domain (5' to 3') coding sequence, wherein the anti-HLA-A2:HPV16E7 scFv comprises a V selected from SEQ ID NO: 2, 34, 82, 194, 282 and 506. H , and a V selected from SEQ ID NO: 10, 42, 90, 202, 290 and 514 L In some embodiments, the present invention includes a nucleic acid molecule encoding HLA-A2:HPV16E7CAR selected from SEQ ID NO:540, 541, 542, 543, 544 and 545.
[0185] In certain embodiments, the polynucleotide encoding the CAR described herein is inserted into a vector. As used herein, the term "vector" refers to a vector into which a polynucleotide encoding a protein can be covalently inserted to cause expression of the protein and / or cloning of the polynucleotide. Such a vector may also be referred to as an "expression vector". The isolated polynucleotide may be inserted into a vector using any suitable method known in the art, such as, but not limited to, the vector may be digested with a suitable restriction enzyme, and then it may be connected to an isolated polynucleotide having matching restriction ends. The expression vector has the ability to incorporate and express heterologous or modified nucleic acid sequences encoding at least part of a gene product that can be transcribed in a cell. In most cases, the RNA molecule is then translated into protein. The expression vector may include a variety of control sequences, which refer to nucleic acid sequences necessary for transcription and possible translation of operably connected coding sequences in a particular host organism. In addition to control sequences for transcription and translation, vectors and expression vectors may also include nucleic acid sequences having other functions, and are discussed below. The expression vector may include other elements, for example, the expression vector may have two replication systems so that it can be maintained in two organisms, such as expressed in human cells, and cloned and amplified in a prokaryotic host.
[0186] The expression vector may have necessary 5' upstream and 3' downstream regulatory elements, such as promoter sequences, such as CMV, PGK and EF1α promoters, ribosome recognition and binding TATA box, and 3'UTR AAUAAA transcription termination sequence, for efficient gene transcription and translation in their respective host cells. Other suitable promoters include Simian Virus 40 (SV40) early constitutive promoter, mouse mammary tumor virus (MMTV), HIVLTR promoter, MoMuLV promoter, avian leukosis virus promoter, EBV immediate early promoter, and Rous sarcoma virus promoter. Human gene promoters may also be used, including but not limited to actin promoter, myosin promoter, hemoglobin promoter and creatine kinase promoter. In certain embodiments, an inducible promoter is also considered to be part of a vector expressing a chimeric antigen receptor. This provides a molecular switch that can turn on or off the expression of a polynucleotide sequence of interest. Examples of inducible promoters include but are not limited to metallothionein promoters, glucocorticoid promoters, progesterone promoters or tetracycline promoters.
[0187] The expression vector may have additional sequences incorporated into the expressed CAR, such as 6×-histidine, c-Myc, and FLAG tags. Therefore, the expression vector can be engineered to include 5' and 3' untranslated regulatory sequences, which can sometimes act as enhancer sequences, promoter regions, and / or terminator sequences, which can promote or enhance the efficient transcription of the nucleic acid of interest carried. On the expression vector. The expression vector can also be modified for replication and / or expression functions (e.g., transcription and translation) in a specific cell type, cell location, or tissue type. The expression vector may include a selection marker for maintaining the vector in a host or recipient cell.
[0188] Examples of vectors are plasmids, autonomously replicating sequences and transposable elements. Other exemplary vectors include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs), bacteriophages, such as lambda phages or M13 phages, and animal viruses. Examples of classes of animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, and papovaviruses (such as SV40). Examples of expression vectors are Lenti-X for expression in mammalian cells. TM Bicistronic expression system (Neo) vector (Clontrch), pClneo vector (Promega); pLenti4 / V5-DEST.TM, pLenti6 / V5-DEST.TM and pLenti6.2N5-GW / lacZ (Invitrogen) for lentiviral-mediated gene transfer and expression in mammalian cells. The coding sequence of CAR disclosed herein can be connected to such an expression vector to express chimeric proteins in mammalian cells.
[0189] In certain embodiments, a nucleic acid encoding the CAR of the present invention is provided in a viral vector. The viral vector may be those derived from a retrovirus, a lentivirus or a foamy virus. As used herein, the term "viral vector" refers to a nucleic acid vector construct comprising at least one element having a viral origin and having the ability to be packaged into a viral vector particle. The viral vector may include coding sequences for various chimeric proteins described herein that replace non-essential viral genes. The vector and / or particle may be used for the purpose of transferring DNA, RNA or other nucleic acids to cells in vitro or in vivo. Various forms of viral vectors are known in the art.
[0190] In certain embodiments, the viral vector comprising the coding sequence of the CAR described herein is a retroviral vector or a lentiviral vector. The term "retroviral vector" refers to a vector containing structural and functional genetic elements mainly from retroviruses. The term "lentiviral vector" refers to a vector containing structural and functional genetic elements mainly from lentiviruses outside of LTR.
[0191] The retroviral vector used in this article can be derived from any known retrovirus (e.g., type c retrovirus, such as Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend, murine stem cell virus (MSCV) and Rous sarcoma virus (RSV). "Retrovirus" of the present invention also includes human T-cell leukemia virus, HTLV-1 and HTLV-2, and the lentivirus family of retroviruses, such as human immunodeficiency virus, HIV-1, HIV-2, simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV) and other classes of retroviruses.
[0192] As used herein, lentiviral vectors refer to vectors derived from lentiviruses, which are a group (or genus) of retroviruses that cause slowly progressive diseases. The viruses included in this group include HIV (human immunodeficiency virus; including HIV type 1 and HIV type 2); visna-maedi; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). The preparation of recombinant lentiviruses can be performed using the method according to Dull et al. and Zufferey et al. (Dull et al., J. Virol., 1998; 72: 8463-8471 and Zufferey et al., J. Virol. 1998; 72: 9873-9880).
[0193] Retroviral vectors (i.e., lentiviral and non-lentiviral) for use in the present invention can be made using standard cloning techniques by combining the desired DNA sequences in the order and orientation described herein (Current Protocols in Molecular Biology, Ausubel, FM et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals; Eglitis, et al. (1985) Science 230:1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85:3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8039-8043; Ferry et al. (1991) Proc. 254:1802-1805; van Beusechem et al. (1992) Proc.Natl.Acad.Sci.USA 89:7640-7644; Kay et al. (1992) Human Gene Therapy 3:641-647; Dai et al. (1992) Proc.Natl.Acad.Sci.USA 89:10892-10895; Hwu et al. (1993) J. Immunol 150:4104-4115; US Pat. No. 4,868,116; US Pat. No. 4,980,286; PCT application WO 89 / 07136; PCT application WO 89 / 02468; PCT application WO 89 / 05345; and PCT application WO 92 / 07573).
[0194] Suitable sources for obtaining retroviral (ie, lentiviral and non-lentiviral) sequences for use in forming vectors include, for example, genomic RNA and cDNA available from commercially available sources, including the American Type Culture Collection (ATCC). Sequences may also be chemically synthesized.
[0195] In order to express HLA-A2: HPV16E7 CAR, the vector can be introduced into the host cell to allow the expression of the polypeptide in the host cell. The expression vector may contain a variety of elements for controlling expression, including but not limited to promoter sequences, transcription start sequences, enhancer sequences, selection markers and signal sequences. As described above, these elements can be appropriately selected by those of ordinary skill in the art. For example, a promoter sequence can be selected to promote the transcription of polynucleotides in the vector. Suitable promoter sequences include but are not limited to T7 promoters, T3 promoters, SP6 promoters, β-actin promoters, EF1a promoters, CMV promoters and SV40 promoters. Enhancer sequences can be selected to enhance the transcription of polynucleotides. A selection marker can be selected to allow host cells without inserted vectors to be selected from those vectors, for example, the selection marker can be a gene that confers antibiotic resistance. A signal sequence can be selected to allow the expressed polypeptide to be transported outside the host cell.
[0196] In order to clone a polynucleotide, a vector can be introduced into a host cell (isolated host cell) to allow replication of the vector itself, thereby amplifying copies of the polynucleotide contained therein. The cloning vector can include sequence components, generally including but not limited to an origin of replication, a promoter sequence, a transcription initiation sequence, an enhancer sequence, and a selective marker. These elements can be appropriately selected by a person of ordinary skill in the art. For example, an origin of replication can be selected to promote autonomous replication of the vector in a host cell.
[0197] In certain embodiments, the disclosure provides a host cell comprising the separation of a vector provided herein. The host cell comprising the vector can be used to express or clone the polynucleotide contained in the vector. Suitable host cells may include, but are not limited to, prokaryotic cells, fungal cells, yeast cells or higher eukaryotic cells, such as mammalian cells. Suitable prokaryotic cells for this purpose include, but are not limited to, true bacteria, such as gram-negative or gram-positive organisms, such as, Enterobacteriaceae, such as Escherichia, such as, Escherichia coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescens, and Shigella, and Bacillus, such as Bacillus subtilis and Bacillus licheniformis, Pseudomonas, such as Pseudomonas aeruginosa, and Streptomyces.
[0198] The CAR of the present invention is introduced into a host cell using transfection and / or transduction techniques known in the art. As used herein, the terms "transfection" and "transduction" refer to the process of introducing an exogenous nucleic acid sequence into a host cell. Nucleic acids can be integrated into host cell DNA or can be maintained outside the chromosome. Nucleic acids can be transiently maintained or can be stably introduced. Transfection can be accomplished by a variety of methods known in the art, including but not limited to calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polyene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and gene gun. Transduction refers to the use of a virus or retroviral vector to deliver a gene by viral infection rather than by transfection. In some embodiments, a retroviral vector is transduced by packaging it into viral particles before contacting the cell. For example, nucleic acids encoding anti-HLA-A2: HPV16E7 CAR carried by a retroviral vector can be transduced into cells by infection and proviral integration.
[0199] As used herein, the term "genetically engineered" or "genetically modified" refers to the addition of additional genetic material in the form of DNA or RNA to the total genetic material in a cell. The terms "genetically modified cell," "modified cell," and "redirected cell" are used interchangeably.
[0200] In particular, the CAR of the present invention is introduced into and expressed in immune effector cells so as to redirect their specificity to a target antigen of interest, e.g., an HLA-A2 displaying a conformational epitope of an HPV16E7 peptide, e.g., amino acid residues 11-19 or 82-90.
[0201] The present invention provides a method for preparing immune effector cells expressing CAR as described herein. In one embodiment, the method includes transfection or transduction of immune effector cells separated from a subject, such as a subject with HPV16E7 related diseases or conditions, so that immune effector cells express one or more CARs as described herein. In certain embodiments, immune effector cells are separated from individuals and genetically modified without further in vitro operation. Such cells can then be directly re-applied to individuals. In other embodiments, before being genetically modified to express CAR, immune effector cells are first activated and stimulated to proliferate in vitro. In this regard, immune effector cells can be cultured before or after being genetically modified (i.e., transduced or transfected to express CAR as described herein).
[0202] Prior to the in vitro manipulation or genetic modification of the immune effector cells described herein, the source of the cell may be obtained from a subject. In particular, the immune effector cells used with the CAR described herein include T cells. Such recombinant T cells are referred to herein as "T bodies (T-bodies)".
[0203] In one embodiment of the present invention, the T body comprises a CAR of the present invention, which comprises an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (e.g., a signaling domain derived from CD3ζ or FcRγ) and / or one or more costimulatory signaling domains derived from costimulatory molecules, such as but not limited to CD28, CD137, CD134 or CD278. In another embodiment of the present invention, the T body comprises a CAR of the present invention, which comprises an extracellular target-specific binding domain, a transmembrane domain, a hinge or spacer between the extracellular binding domain and the transmembrane domain, an intracellular signaling domain. (e.g., a signaling domain derived from CD3ζ or FcRγ) and / or one or more costimulatory signaling domains derived from costimulatory molecules. In another embodiment of the present invention, the T body comprises a T body construct CAR, which comprises an extracellular target-specific binding domain and a T cell receptor constant domain. The extracellular target-specific binding domain suitable for use in a T-body comprising any of the CARs described herein may include a Fab, Fab', (Fab')2, Fv or single-chain Fv (scFv) of an antigen binding protein of the invention.
[0204] T cells can be obtained from many sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue at the site of infection, ascites, pleural effusion, spleen tissue and tumor. In certain embodiments, any number of techniques known to those skilled in the art, such as FICOLL separation, can be used to obtain T cells from a unit of blood collected from a subject. In one embodiment, cells from individual circulating blood are obtained by apheresis. Apheresis products generally contain lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, red blood cells and platelets. In one embodiment, cells collected by apheresis can be washed to remove plasma fractions and cells are placed in appropriate buffer or culture medium for subsequent processing. In one embodiment of the invention, cells are washed with PBS. In another embodiment, the solution after washing lacks calcium, and magnesium may be lacking, or may lack many (if not all) divalent cations. As will be appreciated by those of ordinary skill in the art, the washing step can be accomplished by methods known to those skilled in the art, such as by using a semi-automatic flow-through centrifuge. After washing, the cells can be resuspended in various biocompatible buffers or other saline solutions with or without buffers.In certain embodiments, undesirable components of the apheresis sample can be removed in the medium in which the cells are directly resuspended.
[0205] In some embodiments, for example, by PERCOLL TMGradient centrifugation, by lysing red blood cells and consuming monocytes, separates T cells from peripheral blood mononuclear cells (PBMC). Specific subpopulations of T cells, such as CD28+, CD4+, CD8+, CD45RA+ and CD45RO+T cells, can be further separated by positive or negative selection techniques. For example, the enrichment of T cell populations by negative selection can be completed by combining antibodies for surface markers specific to negatively selected cells. A method used herein is to sort and / or select cells by negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies for cell surface markers present on negatively selected cells. For example, in order to enrich CD4+ cells by negative selection, a mixture of monoclonal antibodies generally includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to separate cell populations of interest for use in the present invention.
[0206] PBMC can be used directly for genetic modification with CAR using the methods described herein. In some embodiments, after separating PBMC, T lymphocytes are further separated, and in some embodiments, cytotoxic T cells and helper T lymphocytes can be classified into immature, memory and effector T cell subsets before or after genetic modification and / or amplification. CD8+ cells can be obtained by using standard methods. In some embodiments, CD8+ cells are further classified into immature, central memory and effector cells by identifying cell surface antigens associated with each of those types of CD8+ cells. In embodiments, memory T cells are present in CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes. After staining with anti-CD8 and anti-CD62L antibodies, PBMCs are divided into CD62L-CD8+ and CD62L+CD8+ parts. In some embodiments, the expression of phenotypic markers of central memory TCM includes CD45RO, CD62L, CCR7, CD28, CD3 and CD127, and is negative for granzyme B. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28 and CD127, and positive for granzyme B and perforin. In some embodiments, naive CD8+ T lymphocytes are characterized by the expression of phenotypic markers of naive T cells, including CD62L, CCR7, CD28, CD3, CD127 and CD45RA.
[0207] In certain embodiments, CD4+T cells are further classified into subgroups. For example, CD4+T helper cells can be classified into naive, central memory and effector cells by identifying cell populations with cell surface antigens. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, naive CD4+T lymphocytes are CD45RO-, CD45RA+, CD62L+CD4+T cells. In some embodiments, central memory CD4+ cells are CD62L positive and CD45RO positive. In some embodiments, effector CD4+ cells are CD62L and CD45RO negative.
[0208] Immune effector cells, such as T cells, can be genetically modified after being separated using known methods, or can be activated and amplified in vitro before being genetically modified (or differentiated in the case of progenitor cells). In another embodiment, immune effector cells, such as T cells, are genetically modified (for example, transduced with a viral vector comprising a nucleic acid encoding CAR) with a chimeric antigen receptor as described herein, and then activated and amplified in vitro. Methods for activating and amplifying T cells are known in the art, and are described in, for example, U.S. Patent No. 6,905,874; U.S. Patent No. 6,867,041; U.S. Patent No. 6,797,514; WO2012079000, US2016 / 0175358. Typically, such methods include contacting PBMC or separated T cells with stimulants and co-stimulators (such as anti-CD3 and anti-CD28 antibodies, typically attached to beads or other surfaces) in a culture medium with appropriate cytokines (such as IL-2). Anti-CD3 and anti-CD28 antibodies attached to the same beads act as "alternative" antigen presenting cells (APC). In other embodiments, T cell proliferation may be activated and stimulated using feeder cells and appropriate antibodies and cytokines using methods as described in US Pat. No. 6,040,177; US Pat. No. 5,827,642; and WO2012129514.
[0209] The present invention provides a population of modified immune effector cells for treating HPV-related diseases or disorders, such as cancer, wherein the modified immune effector cells comprise an HLA-A2:HPV16E7 CAR as disclosed herein.
[0210] The immune effector cells expressing CAR prepared as described herein can be used for methods and compositions for adoptive immunotherapy according to known techniques, or variations thereof that are apparent to those skilled in the art based on the present disclosure. See, e.g., U.S. Patent Application Publication No. 2003 / 0170238 of Gruenberg et al.; see also U.S. Patent No. 4,690,915 of Rosenberg.
[0211] In some embodiments, the cells are formulated by first harvesting the cells from their culture medium, then washing and concentrating the cells in a therapeutically effective amount in a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier). Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott) or Plasma-Lyte A (Baxter), but 5% dextrose in water or Ringer's lactate can also be used. The infusion medium can be supplemented with human serum albumin.
[0212] The therapeutically effective amount of cells in the composition is at least 2 cells (e.g., at least 1 CD8+ central memory T cell and at least 1 CD4+ helper T cell subset), or more usually more than 10 2 cells, and up to 10 6 cells, including 10 8 or 10 9 cells, and can be more than 10 10 The number of cells will depend on the intended end use of the composition, as well as the type of cells contained therein.
[0213] Cells can be autologous or allogeneic to the patient being treated. If desired, the treatment can also include administering mitogens (e.g., PHA) or lymphokines, cytokines and / or chemokines (e.g., IFN-γ, IL-2, IL-12, TNF-α, IL-18 and TNF-β, GM-CSF, IL-4, IL-13, FLT3-L, RANTES, MIP1α, etc.) as described herein to enhance the induction of an immune response.
[0214] The immune effector cell colonies expressing CAR of the present invention can be administered alone, or as a pharmaceutical composition and diluent and / or in combination with other ingredients such as IL-2 or other cytokines or cell colonies. In short, the pharmaceutical composition of the present invention may include immune effector cell colonies expressing CAR, such as T cells as described herein, and one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, mannose, sucrose or dextran, mannitol; protein polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (such as aluminum hydroxide); and preservatives. The composition of the present invention is preferably formulated for intravenous administration.
[0215] The anti-tumor immune response induced in a subject by administering the T cells expressing CAR described herein using the methods described herein or other methods known in the art may include cellular immune responses mediated by cytotoxic T cells capable of killing infected cells, regulatory T cells, and helper T cell responses. Humoral immune responses mediated mainly by helper T cells capable of activating B cells to cause antibody production may also be induced. A variety of techniques can be used to analyze the type of immune response induced by the composition of the present invention, which has been well described in the art; for example, Current Protocols in Immunology, John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober, ed., (2001) John Wiley & Sons, NY, NY.
[0216] Accordingly, the present invention provides a method for treating an individual diagnosed with or suspected of having an HPV-related disease or condition, such as an HPV16E7-positive cancer, or at risk of developing an HPV-related disease or condition, such as an HPV16E7-positive cancer, comprising administering to the individual a therapeutically effective amount of an immune effector cell expressing a CAR as described herein.
[0217] In one embodiment, the present invention provides a method for treating a subject diagnosed with HPV16E7-positive cancer, comprising removing immune effector cells from a subject diagnosed with HPV16E7-positive cancer, modifying the immune effector cells with a vector gene comprising a nucleic acid encoding a chimeric antigen receptor of the present invention, thereby producing a modified immune effector cell population, and administering the modified immune effector cell population to the same subject. In one embodiment, the immune effector cells comprise T cells.
[0218] The method of administering the cell composition described herein includes any method that effectively leads to reintroduction of ex vivo genetically modified immune effector cells that directly express the CAR of the present invention in a subject, or reintroduces genetically modified progenitor cells of immune effector cells that differentiate into mature immune effector cells expressing CAR when introduced into a subject. A method includes transducing peripheral blood T cells ex vivo with a nucleic acid construct according to the present invention, and returning the transduced cells to the subject.
[0219] Therapeutic administration and formulations
[0220] The present invention provides therapeutic compositions comprising anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention, such as antibodies, or antigen binding fragments thereof, or CARs. The therapeutic compositions according to the present invention will be administered together with suitable carriers, excipients and other agents incorporated into the formulation to provide improved transfer, delivery, tolerance, etc. Many suitable formulations can be found in formulas known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, lipid (cationic or anionic)-containing carriers (such as LIPOFECTIN TM ), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsion Carbowax (polyethylene glycol with various molecular weights), semisolid gels, and semisolid mixtures containing Carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52: 238-311.
[0221] The dosage of antigen binding protein, such as antibody, or antigen binding fragment thereof, may vary according to the age and size of the subject to be administered, the target disease, symptoms, route of administration, etc. When the antigen binding protein of the present invention is used to treat a disease or disorder in an adult patient, or for preventing such a disease, it is advantageous to administer the antigen binding protein of the present invention, such as antibody, or antigen binding fragment thereof, usually in a single dose of about 0.1 to about 60 mg / kg body weight, more preferably about 5 to about 60, about 20 to about 50, about 10 to about 50, about 1 to about 10, or about 0.8 to about 11 mg / kg body weight. Depending on the severity of the condition, the frequency and duration of treatment may be adjusted. In certain embodiments, the antigen binding protein of the present invention, such as antibody, or antigen binding fragment thereof, may be administered in an initial dose of at least about 0.1 mg to about 800 mg, about 1 to about 500 mg, about 5 to about 300 mg, or about 10 to about 200 mg, about 100 mg, or about 50 mg. In certain embodiments, an initial dose can be followed by administration of a second or more subsequent doses of an antigen binding protein, such as an antibody, or an antigen binding fragment thereof, in an amount that may be about the same as or less than the initial dose, wherein the subsequent doses are separated by at least 1 to 3 days; at least 1 week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.
[0222] Various delivery systems are known and can be used to administer the pharmaceutical compositions of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem. 262: 4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, e.g., by infusion or bolus injection, absorbed through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered with other biologically active agents. Administration can be systemic or local. The pharmaceutical compositions can also be delivered in vesicles, particularly liposomes (see, e.g., Langer (1990) Science 249: 1527-1533).
[0223] The use of nanoparticles to deliver antigen-binding proteins of the present invention, such as antibodies, or antigen-binding fragments thereof is also envisioned herein. Antigen-binding protein-conjugated nanoparticles can be used for treatment and diagnostic applications. Antigen-binding protein-conjugated nanoparticles and preparation and use methods thereof are described in detail by Arruebo, M. et al. 2009 ("Antibody-conjugated nanoparticles for biomedical applications" in J. Nanomat. Volume 2009, Article ID 439389, 24 pages, doi: 10.1155 / 2009 / 439389), which is incorporated herein by reference. Nanoparticles can be developed and conjugated to antigen-binding proteins contained in pharmaceutical compositions to target tumor cells or autoimmune tissue cells or virus-infected cells. Nanoparticles for drug delivery have also been described in, for example, U.S. Patent No. 8,257,740, or U.S. Patent No. 8,246,995, each of which is incorporated herein by reference in its entirety.
[0224] In some cases, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. In yet another embodiment, the controlled release system can be placed near the target of the composition, so only a portion of the systemic dose is required.
[0225] Injectable preparations can include dosage forms for intravenous, subcutaneous, intradermal, intracranial, intraperitoneal and intramuscular injection, infusion, etc. These injectable preparations can be prepared by known methods. For example, injectable preparations can be prepared, for example, by dissolving, suspending or emulsifying the above-mentioned antigen-binding protein or its salt in a conventional sterile aqueous medium or oily medium for injection. As aqueous media for injection, there are, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, etc., which can be used in combination with suitable solubilizers such as alcohols (e.g., ethanol), polyols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 moles) adduct of hydrogenated castor oil)], etc. As oily media, there are, for example, sesame oil, soybean oil, etc., which can be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, etc. The injection prepared in this way is preferably filled in a suitable ampoule.
[0226] The pharmaceutical compositions of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, pen delivery devices readily find application in delivering the pharmaceutical compositions of the present invention. Such pen delivery devices may be reusable or disposable. Reusable pen delivery devices typically utilize a replaceable cartridge containing the pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable delivery. Rather, the disposable pen delivery device is prefilled with the pharmaceutical composition held in a reservoir within the device. Once the pharmaceutical composition in the container is emptied, the entire device will be discarded.
[0227] Numerous reusable pen and auto-injector delivery devices have applications in subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include, but are not limited to, the AUTOPEN TM (Owen Mumford,Inc.,Woodstock,UK),DISETRONIC TM Pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX75 / 25 TM Pen,HUMALOG TM Pen,HUMALIN 70 / 30 TM Pen(Eli Lilly and Co.,Indianapolis,IN),NOVOPEN TM I,II and III(Novo Nordisk,Copenhagen,Denmark),NOVOPEN JUNIOR TM(NovoNordisk,Copenhagen,Denmark),BD TM Pen(Becton Dickinson,Franklin Lakes,NJ),OPTIPEN TM ,OPTIPEN PRO TM ,OPTIPEN STARLET TM , and OPTICLIK TM (Sanofi-Aventis, Frankfurt, Germany), to name a few. Examples of disposable pen delivery devices useful for subcutaneous delivery of the pharmaceutical compositions of the present invention include, but are certainly not limited to, SOLOSTAR TM PE pen (Sanofi-Aventis), FLEXPEN TM (Novo Nordisk), and KWIKPEN TM (Eli Lilly), SURECLICK TM Autoinjector(Amgen,Thousand Oaks,CA),thePENLET TM (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP) and HUMIRA TM pen (AbbottLabs, Abbott Park, IL), to name a few.
[0228] Advantageously, the pharmaceutical composition for oral or parenteral use is prepared into a unit dosage form suitable for mounting a certain dose of active ingredient. Such unit dosage forms include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of antigen-binding protein contained is generally about 5 to about 500 mg per dosage form in a unit dose; particularly in the form of an injection, it is preferred that for other dosage forms, the antigen-binding protein is contained in about 5 to about 100 mg and about 10 to about 250 mg.
[0229] Therapeutic uses of antigen binding proteins
[0230] The antibodies of the present invention are particularly useful for treating, preventing and / or ameliorating any disease or condition associated with or mediated by HPV16. For example, the present invention provides methods for treating HPV-related diseases or conditions, such as HPV-related cancers (e.g., HPV16E7-positive cancers) (tumor growth inhibition) and / or HPV infection, by administering an anti-HLA-A2:HPV16E7 antigen binding protein as described herein (or a pharmaceutical composition comprising an anti-HLA-A2:HPV16E7 antigen binding protein) to a subject in need of such treatment, and uses of an anti-HLA-A2:HPV16E7 antigen binding protein (or a pharmaceutical composition comprising an anti-HLA-A2:HPV16E7 antigen binding protein) for treating HPV-related cancers (tumor growth inhibition) and / or HPV infection. The antigen binding proteins of the present invention can be used to treat, prevent and / or ameliorate a disease or condition or condition, such as an HPV-related cancer or HPV infection and / or to improve at least one symptom associated with such a disease, condition or condition. In the context of the treatment methods described herein, the anti-HLA-A2:HPV16E7 antigen binding protein can be administered as monotherapy (ie, as the sole therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).
[0231] In some embodiments of the invention, the antibodies described herein can be used to treat subjects with primary or recurrent cancers, including but not limited to HPV-related cancers, such as squamous cell carcinomas, such as head and neck squamous cell carcinomas, cervical cancer, anorectal carcinoma, oropharyngeal cancer.
[0232] Antigen binding proteins can be used to treat early or late symptoms of HPV-related cancers. In one embodiment, the antibodies or fragments thereof of the present invention can be used to treat advanced or metastatic cancers. Antigen binding proteins can be used to reduce or inhibit or shrink tumor growth. In certain embodiments, treatment with the antigen binding proteins of the present invention results in more than 40% regression, more than 50% regression, more than 60% regression, more than 70% regression, more than 80% regression or more than 90% regression of the tumor in the subject. In certain embodiments, antigen binding proteins can be used to prevent the recurrence of tumors. In certain embodiments, antigen binding proteins can be used to prolong progression-free survival or overall survival of subjects with HPV-related cancers. In some embodiments, antibodies can be used to reduce toxicity caused by chemotherapy or radiotherapy while maintaining long-term survival in patients with HPV-related cancers.
[0233] In certain embodiments, the antigen binding proteins of the invention can be used to treat subjects with chronic HPV infection. In some embodiments, the antigen binding proteins of the invention can be used to reduce viral titers in a host.
[0234] One or more antibodies of the invention may be administered to alleviate or prevent or reduce the severity of one or more symptoms or conditions of a disease or disorder.
[0235] Also contemplated herein is the prophylactic use of one or more antibodies of the invention to patients at risk for developing a disease or disorder, such as an HPV-associated disease or disorder (eg, HPV-associated cancer) and HPV infection.
[0236] In a further embodiment of the invention, the antibodies of the invention are used to prepare a pharmaceutical composition for treating a patient suffering from an HPV-related disease or condition, such as an HPV-related cancer, or an HPV infection. In another embodiment of the invention, the antibodies of the invention are used as an adjunct therapy with any other agent or any other therapy known to those skilled in the art to be useful for treating an HPV-related cancer or an HPV infection.
[0237] Combination therapies and formulations
[0238] Combination therapy may include anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention, such as CAR of the present invention (e.g., immune effector cells comprising CAR of the present invention) or pharmaceutical compositions of the present invention, and any additional therapeutic agent that may be advantageously combined with the antigen binding proteins of the present invention. The antigen binding proteins of the present invention may be synergistically combined with one or more anticancer drugs or therapies for treating or suppressing HPV16E7-related diseases or conditions, such as HPV-positive cancers, for example, squamous cell carcinoma, cervical cancer, anorectal cancer, head and neck cancer, or oropharyngeal cancer.
[0239] It is contemplated herein to use the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention in combination with immunostimulatory and / or immune supportive therapies to inhibit tumor growth, and / or enhance cancer patient survival. Immunostimulatory therapies include direct immunostimulatory therapies that enhance immune cell activity by "releasing the brakes" or "stepping on the gas" on suppressed immune cells to activate immune responses. Examples include targeting other checkpoint receptors, vaccination, and adjuvants. Immune supportive modalities can increase the antigenicity of tumors by promoting immunogenic cell death, inflammation, or having other indirect effects that promote anti-tumor immune responses. Examples include radiation, chemotherapy, anti-angiogenic agents, and surgery.
[0240] In various embodiments, one or more antigen binding proteins of the invention can be used in conjunction with a PD-1 inhibitor (e.g., an anti-PD-1 antibody such as nivolumab, pembrolizumab, pidilizumab, BGB-A317 or REGN2810), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody such as avelumab, atezolizumab, durvalumab, MDX-1105 or REGN3504), a CTLA-4 inhibitor (e.g., ipilimumab), a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, a GITR inhibitor, an antagonist of another T cell co-inhibitor or ligand (e.g., an antibody to CD-28, 2B4, LY108, LAIR1, ICOS, CD160 or VISTA), an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist [e.g., a "VEGF-trap" such as aflibercept or other VEGF inhibitory fusion proteins such as U.S. Pat. No. 7,087,411, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab, or ranibizumab) or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib or pazopanib)], Ang2 inhibitors (e.g., nesvacumab), transforming growth factor β (TGFβ) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), CD20 inhibitors (e.g., anti-CD20 antibodies, such as rituximab), antibodies against tumor-specific antigens [e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin 1, MART-1 and CA19-9], vaccines (e.g., bacillus Calmette-Guérin, cancer vaccines), adjuvants that increase antigen presentation (e.g., granulocyte-macrophage colony stimulating factor), bispecific antibodies (e.g., CD3×CD20 bispecific antibodies, or PSMA×CD3 bispecific antibodies), cytotoxins, chemotherapeutic agents (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine), cyclophosphamide, radiation therapy, surgery, IL-6R inhibitors (e.g., sarilumab), IL-4R inhibitors (e.g., dupilumab), IL-10 inhibitors, cytokines (e.g., IL-2, IL-7, IL-21, and IL-15), antibody-drug conjugates (ADCs) (e.g., anti-CD19-DM4 ADC and anti-DS6-DM4 ADC), anti-inflammatory drugs (e.g., corticosteroids and non-steroidal anti-inflammatory drugs), dietary supplements, such as antioxidants, or any other therapeutic treatment for cancer. In certain embodiments, the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention can be used in combination with HPV vaccines. Exemplary HPV vaccines include Gardasil, Gardasil 9, and Cervarix, Lm-LLo-E7 (ADXS11-001; ADXS-HPV; Advaxis,Inc.); GLBL101c (GENOLAC BL Corp); TA-HPV (European Organization for Research and Treatment of Cancer (EORTC)); TG4001 (Transgene / Roche); MVA E2 (Instituto Mexicano del Seguro Social); HPV16-SLP (ISA Pharmaceuticals); GL-0810 (Gliknik Inc.); Pepcan+Candin (University of Arkansas); GTL001 (ProCervix; Genticel); TA-CIN (Xenova Research Limited); TA-CIN+TA-HPV (Celtic Pharma); pNGVL4a-sig / E7(detox) / HSP70+TA-HPV (Sidney Kimmel Comprehensive Cancer Center); pNGVL4a-CRT / E7(detox) (Sidney Kimmel Comprehensive Cancer Center) Center); GX-188E (Genexine, Inc); VGX-3100 (Inovio Pharmaceuticals); dendritic cells pulsed with HPV-16 and HPV-18E7 and keyhole limpet hemocyanin (National Institutes of Health); DC pulsed with HPV+ tumor lysate (Department of Biotechnology (DBT, Govt. of India)); PDS0101 (PDS Biotechnology Corp); ProCervix (Genticel); GX-188E (Genexine,Inc); pNGVL4a-CRT / E7(detox) (Sidney KimmelComprehensive Cancer Center); pNGVL4a-sig / E7(detox) / HSP70+TA-HPV (Sidney KimmelComprehensive Cancer Center); TVGV-1+GPI-0100 (THEVAX Genetics Vaccine Co.); Pepcan+Candin (University of Arkansas); ISA101 (SLP-HPV-01; HPV16-SLP; ISAPharmaceuticals); ADXS11-001 (Lm-LLo-E7; Advaxis, Inc.); ISA101 (SLP-HPV-01; HPV16-SLP; ISA Pharmaceuticals); DPX-E7 (Dana-Farber Cancer Institute); ADXS11-001 (Lm-LLo-E7; Advaxis, Inc.); INO-3112 (VGX-3100 + INO-9012; Inovio Pharmaceuticals); ADXS11-001 (Lm-LLo-E7; Advaxis, Inc.); INO-3112 (VGX-3100 + INO-9012; Inovio Pharmaceuticals); ISA101 (SLP-HPV-01; HPV16-SLP; ISA Pharmaceuticals); and TA-CIN + GPI-0100 (Sidney Kimmel Comprehensive Cancer Center). In certain embodiments, the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention can be used in combination with cancer vaccines including dendritic cell vaccines, oncolytic viruses, tumor cell vaccines, etc. to enhance anti-tumor responses. Examples of cancer vaccines that can be used in conjunction with the anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention include MAGE3 vaccines for melanoma and bladder cancer, MUC1 vaccines for breast cancer, EGFRv3 (e.g., Rindopepimut) for brain cancer (including glioblastoma multiforme), or ALVAC-CEA (for CEA+ cancers).
[0241] In certain embodiments, the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention may be administered in combination with radiotherapy in the method to produce a long-lasting anti-tumor response and / or enhance the survival of patients with cancer. In some embodiments, the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention may be administered before, simultaneously with, or after radiotherapy is administered to cancer patients. For example, one or more doses of radiotherapy may be administered to the tumor lesion, followed by one or more doses of the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention. In some embodiments, radiotherapy may be administered locally to the tumor lesion to enhance the local immunogenicity of the patient's tumor (adjuvant radiation) and / or to kill tumor cells (ablative radiation), followed by systemic administration of the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention. For example, intracranial radiation may be administered in combination with systemic administration of the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention to patients with brain cancer (e.g., glioblastoma multiforme). In certain embodiments, the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention may be administered in combination with radiation therapy and a chemotherapeutic agent (eg, temozolomide) or a VEGF antagonist (eg, aflibercept).
[0242] In certain embodiments, the anti-HLA-A2: HPV16E7 antigen binding proteins of the present invention can be administered in combination with one or more antiviral drugs for treating chronic HPV infection. Examples of antiviral drugs include, but are not limited to, zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine and corticosteroids.
[0243] Additional therapeutically active agents / components may be administered before, simultaneously with, or after the administration of the anti-HLA-A2:HPV16E7 antigen binding protein of the present invention. For the purposes of this disclosure, such an administration regimen is considered to be the administration of the anti-HLA-A2:HPV16E7 antigen binding protein "in combination with" a second therapeutically active component.
[0244] The additional therapeutically active component can be administered to the subject prior to administration of the anti-HLA-A2: HPV16E7 antigen binding protein of the present invention. For example, if the first component is administered 1 week before the second component, 72 hours before, 60 hours before, 48 hours before, 36 hours before, 24 hours before, 12 hours before, 6 hours before, 5 hours before, 4 hours before, 3 hours before, 2 hours before, 1 hour before, 30 minutes before, 15 minutes before, 10 minutes before, 5 minutes before, or less than 1 minute before, the first component can be considered to be administered "before" the second component. In other embodiments, the additional therapeutically active component can be administered to the subject after administration of the anti-HLA-A2: HPV16E7 antigen binding protein of the present invention. For example, if the first component is administered 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours after the administration of the second component, then the first component can be considered to be administered after the second component. In some other embodiments, the additional therapeutically active component can be administered to the subject simultaneously with the administration of the anti-HLA-A2: HPV16E7 antigen binding protein of the present invention. For the purposes of the present invention, "simultaneous" administration includes, for example, administering the anti-HLA-A2: HPV16E7 antigen binding protein and the additional therapeutically active component to the subject in a single dosage form (e.g., co-formulated), or administering to the subject in separate dosage forms within about 30 minutes or less of each other. If administered in separate dosage forms, each dosage form can be administered by the same route (e.g., both the anti-HLA-A2:HPV16E7 antigen binding protein and the additional therapeutically active component can be administered intravenously, subcutaneously, etc.); or, each dosage form can be administered by different routes (e.g., the anti-HLA-A2:HPV16E7 antigen binding protein can be administered intravenously, while the additional therapeutically active component can be administered subcutaneously). In any case, for the purposes of this disclosure, administering the components in a single dosage form, in separate dosage forms by the same route, or in separate dosage forms by different routes is considered to be "administered simultaneously." For the purposes of this disclosure, administering the anti-HLA-A2:HPV16E7 antigen binding protein "before," "at the same time," or "after" the administration of the additional therapeutically active component (these terms are defined herein above) is considered to be administering the anti-HLA-A2:HPV16E7 antigen binding protein "in combination with" the additional therapeutically active component.
[0245] The present invention includes pharmaceutical compositions in which the anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention are co-formulated with one or more additional therapeutically active ingredients as described elsewhere herein, using a variety of dosage combinations.
[0246] Administration regimen
[0247] According to certain embodiments of the present invention, multiple doses of anti-HLA-A2: HPV16E7 antigen binding protein (or a pharmaceutical composition comprising a combination of anti-HLA-A2: HPV16E7 antigen binding protein and any additional therapeutically active agent mentioned herein) can be administered to a subject over a specified time course. The method according to this aspect of the present invention comprises sequentially administering multiple doses of the anti-HLA-A2: HPV16E7 antigen binding protein of the present invention to a subject. As used herein, "sequential administration" means that each dose of the anti-HLA-A2: HPV16E7 antigen binding protein is administered to a subject at different time points, for example, on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes a method comprising sequentially administering to a patient a single starting dose of an anti-HLA-A2: HPV16E7 antigen binding protein, followed by one or more second doses of an anti-HLA-A2: HPV16E7 antigen binding protein, and optionally followed by one or more third doses of an anti-HLA-A2: HPV16E7 antigen binding protein. The anti-HLA-A2:HPV16E7 antigen binding protein can be administered at a dose of 0.1 mg / kg to 100 mg / kg of the subject's body weight.
[0248] The terms "initial dose", "second dose" and "third dose" refer to the time sequence of administering the anti-HLA-A2: HPV16E7 antigen binding protein of the present invention. Therefore, the "initial dose" is the dose administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "second dose" is the dose administered after the initial dose; the "third dose" is the dose administered after the second dose. The initial, second and third doses may all contain the same amount of anti-HLA-A2: HPV16E7 antigen binding protein, but may generally differ from each other in the frequency of administration. In certain embodiments, however, the amount of anti-HLA-A2: HPV16E7 antigen binding protein contained in the initial, second and / or third doses varies from each other during the course of treatment (e.g., appropriately adjusted upward or downward). In certain embodiments, two or more (e.g., 2, 3, 4 or 5) doses are administered as a "loading dose" at the beginning of the treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered on a less frequent basis.
[0249] In certain embodiments, the amount of anti-HLA-A2:HPV16E7 antigen binding protein contained in the initial, second and / or third doses may be suboptimal or subtherapeutic. As used herein, the term "subtherapeutic" or "suboptimal" refers to an antibody dose that is administered at a level that is too low to produce a therapeutic effect or is below the level required to treat a disease, such as cancer.
[0250] In certain exemplary embodiments of the invention, each second and / or third dose is administered 1 to 26 (e.g., 1, 1 1 / 2,2,2 1 / 2,3,3 1 / 2,4,4 1 / 2,5,5 1 / 2,6,6 1 / 2,7,7 1 / 2,8,8 1 / 2,9,9 1 / 2,10,10 1 / 2,11,11 1 / 2,12,12 1 / 2,13,13 1 / 2,14,14 1 / 2,15,15 1 / 2,16,16 1 / 2,17,17 1 / 2,18,18 1 / 2,19,19 1 / 2,20,20 1 / 2,21,21 1 / 2,22,22 1 / 2,23,23 1 / 2,24,24 1 / 2,25,25 1 / 2,26,26 1 / 2 or more) weeks. As used herein, the phrase "immediately preceding dose" means, in a sequence of multiple administrations, the dose of anti-HLA-A2:HPV16E7 antigen binding protein administered to a patient prior to the next dose in the administration sequence, with no intervening doses.
[0251] The method according to this aspect of the invention may include administering any number of second and / or third doses of anti-HLA-A2: HPV16E7 antigen binding proteins to the patient. For example, in certain embodiments, only a single second dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) second doses are administered to the patient. Similarly, in certain embodiments, only a single third dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) third doses are administered to the patient.
[0252] In embodiments involving multiple second doses, each second dose can be administered at the same frequency as other second doses. For example, each second dose can be administered to the patient 1-2 weeks or 1-2 months after the previous dose. Similarly, in embodiments involving multiple third doses, each third dose can be administered at the same frequency as other third doses. For example, each third dose can be administered to the patient 2-12 weeks after the previous dose. In certain embodiments of the present invention, the frequency of administering the second and / or third dose to the patient can change during the course of the treatment regimen. The frequency of administration can also be adjusted during the doctor's treatment according to the needs of individual patients after clinical examination.
[0253] Diagnostic Uses of Antigen Binding Proteins
[0254] The anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be used to detect and / or measure HPV16E7 in a sample, for example, for diagnostic purposes. Some embodiments contemplate the use of one or more antigen binding proteins of the present invention in an assay to detect a disease or condition, such as an HPV-related disease or condition, such as an HPV16E7-positive cancer, or an HPV infection. An exemplary diagnostic assay for HPV16E7 can include, for example, contacting a sample obtained from a subject (e.g., a patient) with an anti-HLA-A2:HPV16E7 antigen binding protein of the present invention, wherein the anti-HLA-A2:HPV16E7 antigen binding protein is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively separate HPV16E7 from a subject sample. Alternatively, an unlabeled anti-HLA-A2:HPV16E7 antigen binding protein can be combined with a second antigen binding protein, such as an antibody, that is itself detectably labeled for diagnostic applications. The detectable label or reporter molecule can be a radioactive isotope, such as 3 H, 14 C, 32 P, 35 S or 125I; fluorescent or chemiluminescent moieties, such as fluorescein isothiocyanate, or rhodamine; or enzymes, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure HPV16E7 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
[0255] Samples that can be used for the HPV16E7 diagnostic assay according to the present invention include any tissue or fluid sample that can be obtained from a subject, which contains a detectable amount of HPV16E7 protein or fragment thereof under normal or pathological conditions. Typically, the level of HPV16E7 obtained from a specific sample of a healthy patient (e.g., a patient who does not suffer from an HPV16E7-related disease or condition, e.g., an HPV16E7-positive cancer) will be measured to initially establish a baseline or standard level of HPV16E7. This HPV16E7 baseline level can then be compared to the level of HPV16E7 measured in a sample obtained from an individual suspected of having a cancer-related condition, or symptoms associated with such a condition.
[0256] Antigen binding proteins specific for HPV16E7 may not include additional markers or modules, or they may include N-terminal or C-terminal tags or portions. In one embodiment, the marker or portion is biotin. In a binding assay, the position of the marker (if any) can determine the direction of the peptide relative to the surface of the binding peptide. For example, if the surface is coated with avidin, a peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide will be at the far end of the surface.
[0257] Aspects of the present invention relate to using the disclosed antigen binding proteins as markers for predicting the prognosis of patients with HPV16E7 positive cancer or HPV infection. The antigen binding proteins of the present invention can be used in diagnostic assays to assess the prognosis of a patient's cancer and predict survival.
[0258] Example
[0259] The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to prepare and use the methods and compositions of the present invention and are not intended to limit the scope of what the inventors believe to be their invention. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is degrees Celsius, room temperature is about 25°C, and pressure is at or near atmospheric pressure.
[0260] Example 1: Generation of human antibodies against HLA-A2: HPV16E7
[0261] Human antibodies against HLA-A2:HPV16E7 were generated using a peptide fragment of HPV16E7 conjugated to HLA-A2, comprising amino acids 11-19 (YMLDLQPET; SEQ ID NO: 538) of GenBank Accession NP_041326.1 (SEQ ID NO: 537) or amino acid residues 82-90 (LLMGTLGIV; SEQ ID NO: 539) of GenBank Accession NP_041326.1 (SEQ ID NO: 537). Mice (i.e., engineered mice containing DNA encoding human immunoglobulin heavy chains and kappa light chain variable regions) are directly administered with an immunogen together with an adjuvant to stimulate an immune response, for example, as described in U.S. Patent No. 8,502,018. The antibody immune response is monitored by an HLA-A2: HPV16E7 specific immunoassay. When the desired immune response is achieved, splenocytes are harvested and fused with mouse myeloma cells to maintain their viability and form hybridoma cell lines. Hybridoma cell lines are screened and selected to identify cell lines that produce HLA-A2: HPV16E7 specific antibodies. Using this technology and the above-mentioned immunogen, several anti-HPV16E7 chimeric antibodies (i.e., antibodies with human variable domains and mouse constant domains) were obtained. Exemplary antibodies generated in this manner are designated as follows: H4sH17364N; H4sH17368N2; H4sH17930N; H4sH17930N2; H4sH17363N and H4sH17368N3.
[0262] Anti-HLA-A2:HPV16E7 antibodies were also isolated directly from antigen-positive B cells (from any immunized mouse) without fusion with myeloma cells, as described in U.S. Pat. No. 7,582,298, which is incorporated herein by reference in its entirety. Using this approach, several fully human anti-HLA-A2:HPV16E7 antibodies (i.e., antibodies having human variable domains and human constant domains) were obtained.
[0263] Exemplary antibodies produced according to the above methods are named as follows: H4sH17670P; H4sH17672P; H4sH17673P; H4sH17675P; H4sH17680P; H4sH17697P; H4sH17707P; H4sH17715P; H4sH17726P; H4sH17730P; H4sH21051P; H4sH21054P; H4sH21055P; H 4sH21058P; H4sH21064P; H4sH21073P; H4sH21077P; H4sH21079P; H4sH21080P; H4sH21083P; H4sH21 086P; H4sH21090P; H4sH21091P; H4sH21093P; H4sH21099P; H4sH21100P; H4sH21103P; and H4sH21104P.
[0264] The biological properties of exemplary antibodies produced according to the methods of this example are described in detail in the Examples set forth below.
[0265] Example 2: Heavy and light chain variable region amino acid and nucleotide sequences
[0266] Table 1 lists the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-HLA-A2: HPV16E7 antibodies of the present invention. Table 2 lists the corresponding nucleic acid sequence identifiers.
[0267] Table 1: Amino Acid Sequence Identifiers
[0268]
[0269]
[0270] Table 2: Nucleotide sequence identifiers
[0271]
[0272]
[0273] Antibodies are generally referred to herein according to the following nomenclature: an Fc prefix (e.g., "H1M," "H4sH," "H4H," etc.), followed by a numerical identifier (e.g., "17670," "17930," etc., as shown in Table 1), followed by a "P," "N," or "N2" suffix. Thus, according to this nomenclature, an antibody may be referred to herein as, for example, "H4sH17670P," "H4sH17930N," "H4sH17368N2," etc. The H4sH and H4H prefixes on the antibody names used herein indicate a particular Fc region isotype of the antibody. For example, an "H4sH" antibody has a human IgG4 Fc with 2 or more amino acid changes, as disclosed in U.S. Patent Publication No. 20140243504 (incorporated herein in its entirety), an "H4H" antibody has a human IgG4 Fc with a serine to proline mutation (S108P) in the hinge region, and an "H1M" antibody has a mouse IgG1 Fc, "H2M" antibodies have mouse IgG2 Fc (as indicated by the first "H" in the antibody name, all variable regions are fully human). As will be appreciated by one of ordinary skill in the art, an antibody having a particular Fc isotype can be converted to an antibody having a different Fc isotype (e.g., an antibody having a mouse IgG1 Fc can be converted to an antibody having a human IgG4, etc.), but in any case, the variable domains (including CDRs) (as identified by the numerical identifiers shown in Table 1) will remain unchanged and the properties of antigen binding are expected to be the same or substantially similar, regardless of the nature of the Fc domain.
[0274] In certain embodiments, the selected antibody with mouse IgG1 Fc is converted to an antibody with human IgG4 Fc. In certain embodiments, the antibody comprises a human IgG4 Fc with 2 or more amino acid changes, as described in U.S. Patent No. 20100331527 (incorporated herein in its entirety). In one embodiment, the IgG4 Fc domain comprises a serine to proline mutation (S108P) in the hinge region to promote dimer stabilization.
[0275] Table 3 lists the amino acid sequence identifiers of the heavy and light chain sequences of selected antibodies of the present invention.
[0276] Table 3: Heavy and light chain sequence identifiers
[0277]
[0278] Example 3: Analysis of variable gene utilization
[0279] To analyze the structure of the generated antibodies, nucleic acids encoding the variable regions of the antibodies were cloned and sequenced. Based on the nucleic acid sequence and predicted amino acid sequence of the antibodies, the gene usage of each heavy chain variable region (HCVR) and light chain variable region (LCVR) was determined (Table 4).
[0280] Table 4.
[0281]
[0282]
[0283] Example 4: Surface plasmon resonance-derived binding affinity and kinetic constants of human monoclonal anti-HLA-A2: HPV16E7 monospecific antibodies
[0284] The binding affinity and kinetic constants of human anti-HLA-A2 / HPV16E7 antibodies were determined by real-time surface plasmon resonance (SPR; Biacore 4000 or Biacore T-200, GE Healthcare Life Sciences, Pittsburgh, PA) at 25°C. The antibodies were captured on a CM5 Biacore sensor surface (GE Healthcare Life Sciences) derivatized with a monoclonal anti-human Fc antibody (GE, #BR-1008-39) by amine coupling. Various concentrations of monomeric HLA-A2:HPV16E7 peptide complexes containing E7:11-19 peptide (SEQ ID NO:538) or E7:82-90 peptide (SEQ ID NO:539) were injected onto the anti-HLA-A2:HPV16E7 antibody capture surface at a flow rate of 50 μL / min (Biacore T-200) or 30 μL / min (Biacore 4000). Antibody-reagent association was monitored for 4-5 minutes and dissociation was monitored for 10 minutes.All binding studies were performed in HBS-ET buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.05% v / v Surfactant P20).
[0285] Kinetic binding (K a ) and dissociation (K d ) rate constants were determined by fitting the real-time sensorgrams to a 1:1 binding model using Scrubber 2.0c curve fitting software. The binding and dissociation equilibrium constants (K) were calculated from the kinetic rate constants. D ) and dissociation half-life (t1 / 2) are:
[0286] and
[0287] The binding kinetic parameters of the monospecific anti-HLA-A2:HPV16E7 antibodies to the monomeric HLA-A2 / HPV16E7 peptide complex are shown in Tables 5 and 6 below.
[0288] Table 5: Biacore binding affinity of anti-HLA-A2 / HPV16E7 (11-19) antibodies at 25°C
[0289]
[0290] *NB indicates that under the experimental conditions, the HLA-A2:HPV16E7(11-19) peptide reagent did not bind to the captured anti-HLA-A2:HPV16E7 monoclonal antibody
[0291] Table 6: Biacore binding affinity of anti-HLA-A2 / HPV16E7 (82-90) antibodies at 25°C
[0292]
[0293]
[0294] *NB indicates that under the experimental conditions, the HLA-A2:HPV16E7(82-90) peptide reagent did not bind to the captured anti-HLA-A2:HPV16E7 monoclonal antibody
[0295] The data demonstrate that most anti-HLA-A2 / HPV16E7 antibodies of the invention selectively bind to soluble HLA-A2 / HPV16E7 peptide complexes, some with subnanomolar affinity. Some antibodies, however, do not exhibit binding to HLA-A2 / HPV16E7 complexes.
[0296] Example 5: Prediction of potential off-target peptides
[0297] Given a target 9-mer peptide-HLA-A2 complex, relevant potential off-target peptides were defined based on three criteria: A) the peptide is a 9-mer and is predicted to bind HLA-A2, B) the peptide is similar to the target peptide based on sequence homology, and C) the peptide is derived from a gene expressed in primary, normal tissues. Therefore, to predict potential off-target peptides associated with YMLDLQPET (HPV16E711-19; SEQ ID NO: 538) and LLMGTLGIV (HPV16E782-90; SEQ ID NO: 539), the following method was used (see generally Dhanik, Ankur, et al. (2016) BMC Bioinformatics 17(1): 286).
[0298] As a first step, canonical human protein sequences were downloaded from the UniprotKB database (September 2014 version) (Magrane, Michele, and UniProt Consortium. Database 2011 (2011): bar009) and all 9-mers were extracted. This resulted in 11,118,076 peptides from 20,014 protein sequences.
[0299] Next, use the NetMHCstab network server (version 1.0) ( Kasper W., et al. (2014) Immunology 141(1):18-26) calculated the affinity of these peptides for binding to HLA-A2. Peptides with affinity values <500 nM were predicted to bind to HLA-A2, and the rest were discarded, resulting in a remaining 338,452 peptides.
[0300] The peptide sequences were then evaluated for sequence homology with the target peptide. For each peptide, its degree of similarity (DoS) with the target peptide was calculated. The DoS value represents the number of identical amino acids at the same position between the two peptides. Peptides with a DoS value of less than 6 were rejected, resulting in a remaining 21 peptides in the case of HLA-A2 / HPV16E7:11-19 and a remaining 78 peptides in the case of HLA-A2 / HPV16E7:82-90.
[0301] The genes corresponding to these 21 peptides were examined for expression in basic, normal tissues. The evaluation of this expression was done using gene expression data derived from the GTEx (gene tissue expression) and TCGA (cancer genome atlas) databases provided by OmicSoft (Hu, Jun, et al. Bioinformatics (2012) 28(14): 1933-1934). Data on RPKM (reads per kilobase per million) values from 497 TCGA adjacent normal samples (across 15 basic tissue types) and 2,928 GTEx normal samples (across 22 basic tissue types) were available. Tissues other than breast, cervix, fallopian tube, testis, uterus, and vagina were considered basic. A gene was considered to be expressed in basic, normal tissues if the maximum value of the 95th percentile expression in each basic, normal tissue type in the GTEx and TCGA databases was >= 0.5 RPKM. For HLA-A2 / HPV16E7:11-19 (YMLDLQPET), 10 of the 21 peptides were derived from genes expressed in primary, normal tissues. For HLA-A2 / HPV16E7:82-90 (LLMGTLGIV), 49 of the 78 peptides were derived from genes expressed in primary, normal tissues.
[0302] These 10 peptides constitute predicted off-targets associated with the target YMLDLQPET-HLA-A2 complex (Table 7). Of the 49 potential peptides predicted to constitute possible off-targets associated with the LLMGTLGIV-HLA-A2 complex, 13 were randomly selected for experimental validation and are listed in Table 8.
[0303] Table 7: Predicted off-target peptides similar to HLA-A2 / HPV16E7:11-19 (YMLDLQPET; SEQ ID NO:538)
[0304]
[0305] Table 8: Predicted off-target peptides similar to HLA-A2 / HPV16E7:82-90 (LLMGTLGIV; SEQ ID NO:539)
[0306]
[0307] Example 6: T2 peptide pulse to determine HLA-A2 / HPV16E7 M specificity
[0308] To determine the specificity of anti-HLA-A2 / HPV16E7 monoclonal antibodies, T2 cells were pulsed with peptides loaded with target peptides or off-target peptides (identified in the previous examples). The experiments were performed as follows: T2 cells were cultured in AIM for exogenous loading of HPV16E7 target peptides or off-target peptides. The cells were rinsed in culture medium and counted using a CellometerTM Auto T4 cell counter (Nexcelom Bioscience). Approximately 6,000,000 T2 cells per T-75 flask were cultured at 26°C in 9 mL of AIM containing 10 μg human b2m and 100 μg HPV16 E7 peptide or off-target peptide (Tables 6 and 7). Culture in culture medium for 24 hours. Wash peptide-loaded T2 cells once with PBS without Ca2+ / Mg2+ and count. Peptide-loaded T2 or untreated T2 in cell washing buffer was seeded into a 96-well carbon electrode plate (MULTI-ARRAY high binding plate, MSD) at approximately 10,000 cells per well and incubated at 37°C for 1 hour to allow the cells to attach to the plate. Nonspecific binding sites were blocked for 1 hour using 2% BSA (w / v) in PBS at room temperature. Solutions of anti-HLA-A2 / HPV16E7:11-19, anti-HLA-A2 / HPV16E7:82-90 or control antibodies in a series of dilutions ranging from 1.7 pM to 100 nM, as well as solutions without antibodies, were added to the plate-bound cells. The plate was incubated at room temperature for 1 hour and then washed using an AquaMax2000 plate washer (MDS Analytical Technologies) to remove unbound antibodies. SULFO-TAG specific for Fcγ fragments was used. TM Conjugated goat polyclonal anti-human IgG antibody (JacksonImmunoresearch, Meso Scale Discovery) detects the antibody bound to the plate for 1 hour at room temperature. After washing, the plate is developed with reading buffer (MSD) according to the manufacturer's recommended procedure, and the luminescent signal is recorded with a SECTOR Imager 600 (Meso Scale Discovery) instrument. The luminescent intensity measured in relative light units (RLU) is recorded to indicate the binding intensity of each antibody in the concentration range. The cell binding signal ratio of each anti-HLA-A2 / HPV16E7 antibody relative to the isotype control at 11nM is reported in Tables 8 and 9 and is a specific indication. At a concentration of 11nM, most antibodies show little binding to T2 untreated cells. Not all antibodies are tested with all corresponding relevant off-target peptides. Those that have not been tested are marked as NT, i.e., "untested". Antibodies with a binding ratio greater than 15 were labeled (+++), antibodies with a ratio equal to or less than 15 but greater than or equal to 10 were labeled (++), antibodies with a ratio less than 10 but greater than or equal to 3 were labeled (+), and antibodies with a binding ratio less than 3 were classified as non-binders and indicated as (-). In addition, the direct binding signal (in RLU) was analyzed as a function of antibody concentration and analyzed using GraphPad Prism TM The data were fit to a sigmoidal (four-parameter logistic) dose-response model. When possible, the EC 50 The EC values, defined as the antibody concentration at which 50% of the maximum binding signal was detected on the cells, indicate the potency of each antibody. 50The values are also reported in Tables 9 and 10.
[0309] Ten of the 13 anti-HLA-A2 / HPV16E7:11-19 antibodies of the present invention bind to the HLA-A2 / peptide complex on the surface of T2 cells. Seven of these 10 antibodies (H4sH17670P; H4sH17675P; H4sH17363N; H4sH17364N; H4sH17930N; H4sH17930N2; and H4sH21064P) are specific for the HLA-A2 / HPV16E7:11-19 complex. Three antibodies (H4sH17672P, H4sH21079P, H4sH21080P) show EC 50 Values below 1.1 nM showed higher potency. Three antibodies (H4sH17673P, H4sH17680P, H4sH17697P) did not bind to T2 peptide loaded cells, indicated by (-) in the first column of Table 9.
[0310] Table 9 summarizes the cell binding results on T2 cells loaded with HPV16E7:82-90 target and predicted off-target peptides. 16 of the 21 anti-HLA-A2 / HPV16E7:82-90 mAbs of the present invention bind to the HLA-A2 / peptide complex on the surface of T2 cells. Only 2 mAbs in this group (H4sH17368N2, H4sH21086P) show specificity for the HLA-A2 / HPV16E7 82-90 complex. 5 antibodies (H4sH17730P, H4sH21051P, H4sH21054P, H4sH21055P, H4sH21077P) do not bind to T2 peptide-loaded cells, which are indicated by (-) in Table 10.
[0311]
[0312]
[0313]
[0314] As shown in Tables 9 and 10, the anti-HLA-A2:HPV16E7 antigen binding protein of the present invention binds only to a specific HPV peptide presented by HLA-A2 with high specificity (SEQ ID NO: 538 in Table 9, or SEQ ID NO: 539 in Table 10), and does not bind to any off-target peptides presented by HLA-A2.
[0315] Example 7: Binding specificity analysis using peptide-pulsed T2 cells and FACS analysis
[0316] The relative binding and specificity of the HPV16E7 antibody was assessed by flow cytometry on NIH3T3 cells expressing the HLA-A2 complex presenting HPV 11-19 peptides (3T3 / HLA.A2 / hB2M / HPV16E7:11-19) or HPV82-90 peptides (3T3 / HLA.A2 / hB2M / HPV16E7:82-90). NIH3T3 cells expressing HLA complexes were transfected with human HLA.A2 (Accession No. P01892), human B2M (Accession No. NP_004039.1) and a ubiquitin peptide cassette (Accession No. AKI85233) containing amino acids 11-19 (SEQ ID NO: 538) or amino acids 82-90 (SEQ ID NO: 539) of HPV16E7 (Lévy F., et al. (1996) Proceedings of the National Academy of Sciences of the United States of America 93(10): 4907-4912; Valmori D, et al. (1999) Journal of Experimental Medicine 189(6): 895-906) using lipofectomine 2000 (Invitrogen, Cat#11668), followed by incubation with 1 μg / ml puromycin, 500 μg / ml G418 and 100 μ g / ml hygromycin were selected for at least 2 weeks and produced. For staining, cells were harvested and counted using cell dissociation buffer (Millipore, Cat # S-004-C). Cells were inoculated in a 96-well V-bottom plate at a density of 200,000 cells / well in staining buffer (PBS (Irving9240) + 2% FBS without calcium and magnesium) (ATCC 30-2020), and stained at 4 ° C for 30 minutes with a three-fold serial dilution (1.7pM-100nM) of a primary antibody. After incubation with a primary antibody, cells were washed once in staining buffer and stained at 4 ° C for 30 minutes with 10 μ g / ml of a secondary antibody conjugated with Alexa-Flour 647 (Jackson ImmunoResearch, Cat # 109-606-170). The cells were then washed with a 50% solution of BD Cytofix (BD, Cat# 554655) diluted in staining buffer and fixed. Samples were run and analyzed on an intelliciyt iQue flow cytometer to calculate mean fluorescence intensity (MFI). MFI values were plotted in Graphpad Prism on a 12-point response curve using a four-parameter logistic equation to calculate EC 50For each dose-response curve, the secondary antibody alone (i.e., not the primary antibody) was also included in the analysis as a continuation of the three-fold serial dilutions and is expressed as the lowest dose. 50 The values (M) and the maximum binding fold (fold change from the highest dose to the lowest dose) are shown in Table 11. Several antibodies specifically bound to the 3T3 / HLA.A2 / hB2M / HPV16E7:11-19 or 3T3 / HLA.A2 / hB2M / HPV16E7:82-90 cell lines. 50 Values ranged from 5-500 nM and fold binding ranged from 1.0× to 43.8×.
[0317] Table 11: FACS binding of HPV16E7 antibodies
[0318]
[0319] Antibodies marked with (*) were run together in separate experiments
[0320] ND=EC 50 Undetermined, when the maximum multiple combined is less than or equal to 2 times
[0321] The specificity of the six HPV16E7:11-19 antibodies was further characterized by evaluating binding to T2 (174CEM.T2) cells pulsed with HPV16E7:11-19, HPV16E7:82-90 or predicted off-target peptides (Table 7). For pulsing, T2 (174CEM.T2) cells were incubated at 1×10 6 The cells were resuspended in AIM V medium (Gibco.Cat#31035-025) at a density of 10 cells / ml. The cells were pulsed by adding 10 μg / ml hB2M (EMD Millipore Cat#475828) and 100 μg / ml of the specified peptide. According to the following scheme, T2 cells were then incubated overnight at 26°C, washed in staining buffer, and stained with the specified antibodies at a concentration of 10 μg / ml. The MFI values were calculated and expressed as a multiple change relative to unstained cells. The relative binding range of these 6 HPV16E7:11-19 antibodies on T2 cells pulsed with HPV16E7:11-19 was 986-1200 times higher than unstained cells. On T2 cells pulsed with other peptides, no significant binding was observed above the isotype control (Table 12).
[0322] Table 12: FACS binding of HPV16E7 antibody to T2-pulsed cells. (Fold change relative to unstained)
[0323]
[0324] Example 8: Epitope Analysis Using Alanine Scanning Peptides
[0325] Alanine scanning was performed to determine which residues in the HPV16E7:11-19 peptide were critical for antibody binding. T2 cells were pulsed with alanine scanning peptides and stained with HPV16E7:11-19 antibodies as described above. The following alanine scanning peptides were used (Table 13).
[0326] Table 13: Alanine scanning peptides used in the study
[0327]
[0328] Conversion of aspartate 14 to alanine (D14A) and glutamine 16 to alanine (Q16A) greatly reduced antibody binding for all antibodies tested. Conversion of tyrosine 11 to alanine (Y11A) reduced binding of H4sH17670P, H4sH17675P, H4sH21064P, and H4sH17930N2; but did not reduce binding of H4sH17363N or H4sH17364N. Conversion of leucine 13 to alanine (L13A) and proline 17 to alanine (P17A) reduced overall antibody binding (Table 14).
[0329] Overall, D14 and Q16 are critical residues for antibody binding.
[0330] Table 14: FACS binding of HPV16 E7 antibodies to T2 cells pulsed with alanine scanning peptides
[0331]
[0332] Example 9: Reformatting HLA-A2 / HPV16E7 Antibody into ScFv for Chimeric Antigen Receptor
[0333] Six HLA-A2 / HPV16E7:11-19 antibodies (17363N, 17364N, 17670P, 17675P, 17930N2 and 21064P) were reformatted into VL-VH single chain variable fragments (ScFv) and placed in a chimeric antigen receptor (CAR) construct using the CD8α hinge and transmembrane domains, 4-1BB co-stimulatory domain and CD3ζ stimulatory domain (SEQ ID NO: 540-545). The HLA-A2 / HPV16E7:11-19 specific CAR was cloned into a lentiviral expression vector (Lenti-X TMBicistronic Expression System (Neo, Clontech Cat#632181) and generate lentiviral particles by Lenti-X Packaging Single-Shot (VSV-G) System (Clontech Cat#631276) according to the manufacturer's protocol. Pre-coated Dishes (Clontech, Cat#T110a), Jurkat cells engineered to express the NFAT luciferase reporter gene (Jurkat / NFATLuccl.3C7) were transduced with 6 different CAR constructs. After selection for at least 2 weeks in 500 μg / ml G418 (Gibco, Cat#11811-098), CAR-T cell lines were generated.
[0334] The activity of the CAR-T lines was evaluated in a CAR-T / antigen presenting cell (APC) bioassay.
[0335] To perform the bioassay, 50,000 Jurkat / NFATLuc cl.3C7 CAR-T cells were added to a Thermo-Nunc 96-well white plate (Thermo Scientific, Cat#136101) in 50 μl of assay medium (RPMI medium with 10% FBS and 1% P / S / G), followed by a 3-fold serial dilution of APCs in 50 μl of assay medium (150,000 cells to 200 cells). The following APCs were used: CASKI (HLA-A2+ / HPV16+), CASKI cells overexpressing a single-chain form of HLA-A2 presenting 11-19 or 82-90 peptides; HEK293 (HLA-A2+ / HPV16-), or C33a (HLA-A2+ / HPV16-). The cell mixture was incubated at 37°C, 5% CO2, and a humidified incubator for 5 hours. NFAT-luciferase activity was measured using Promega One-Glo (Cat# E6130) and a Perkin Elmer Envision plate reader. Relative luciferase units (RLU) were generated and plotted on an 8-point response curve using a four-parameter logistic equation in Graphpad Prism to calculate EC 50Values. For each dose-response curve, the zero APC condition was also included in the analysis as a continuation of the three-fold serial dilution and is represented as the lowest dose. The maximum fold activation was determined by taking the ratio of the highest RLU to the lowest on the curve. All six HLA-A2 / HPV16E7:11-19 CAR-T cell lines were activated by CASKI cells overexpressing the HPV16E7:11-19 peptide, with maximum fold activation ranging from 2.5-32.3 fold. APCs or HEK293 and C33a cells overexpressing the HPV16E7:82-90 peptide did not activate the CAR-T cell lines. Interestingly, one CAR-T cell line using a ScFv from antibody 17675P was activated by natural CASKI cells with a fold activation of 4.1 and an EC 50 The number of cells was 68654 (Table 15).
[0336] Table 15: Activation of HPV16E7 (11-19) CAR-T in CAR-T / APC bioassay
[0337] Jurkat / NFATLuc chimeric antigen receptor construct
[0338]
[0339] ND=EC 50 Undetermined, when the maximum multiple combined is less than or equal to 2 times
[0340] Increasing the amount of HPV16E7:11-19 presenting peptide HLA-A2 should result in increased activation of HLA-HPV16E7:11-19CAR. It has been reported that interferon γ can increase antigen presentation by upregulation of proteasomes through MHC class I molecules (Früh K. and Yang Y. (1999) Curr Opin Immunol. 11 (1): 76-81). Based on this observation, it was determined whether wild-type CASKI cells or HEK293 cells pretreated with interferon γ can lead to increased activation of CAR-T cell lines. CASKI cells and HEK293 cells were pretreated with 500 units / ml recombinant human IFN-γ (Peprotech Cat#300-02) for 48 hours and then used in CAR-T / APC bioassays as described above (Table 16). IFNγ pretreated CASKI cells activated all 6 HPV16E7:11-19CAR-T cell lines, with a multiple activation range of 2.4-10.6.
[0341] Table 16: Activation of HPV16E7 (11-19) CAR-T in the presence of IFN-γ
[0342]
[0343]
[0344] ND=EC 50 Undetermined, when the maximum multiple combined is less than or equal to 2 times
[0345] To further evaluate the specificity of the HPV16E7:11-19CAR-T line in the luciferase assay, we used T2 cells as APCs and pulsed with predicted off-target peptides (Table 17). In short, T2 cells were pulsed with three-fold serial dilutions (1.7pg / ml to 100ng / ml) of the specified peptide. After pulsing, 50,000 CAR-T cells were added to a Thermo-Nunc 96-well white plate (Thermo Scientific, Cat#136101) in 50μl of assay medium. Then, 50,000 pulsed T2 cells were added to the plate in 50μl of assay medium. The cell mixture was incubated for 5 hours at 37°C, 5% CO2, and a humidified incubator. Using Promega One-Glo TM NFAT-luciferase activity was measured using a Perkin Elmer Envision plate reader (Cat# E6130). RLU was plotted on a 12-point response curve in Graphpad Prism using a four-parameter logistic equation to calculate EC 50 Values. For each dose response curve, the unpulsed condition was also included in the analysis as a continuation of the three-fold serial dilution and was expressed as the lowest dose. The maximum multiple activation was determined as described previously. All CAR-T cell lines were activated by T2 cells pulsed with HPV16E7:11-19 peptide. The Jurkat / NFATLuc CART line using the ScFv from antibody 17364N was non-specifically activated by T2 cells pulsed with Endophilin-B1 (SH3GLB1:244-252), chondroitin sulfate synthase 2 (CHPF:463:471) and E3 ubiquitin-protein ligase CBL (CBL:83-91). All other CAR-T cell lines did not have significant activation of any off-target peptides.
[0346] Table 17: Maximum fold activation of HPV16E7 (11-19) CAR-T on T2-pulsed cells.
[0347]
[0348]
[0349] Example 10: Structural analysis of Fab binding to HLA-A2+HPV16E7:11-19 peptide
[0350] In an effort to better understand the specific interactions between antibodies and HLA-peptide complexes, X-ray crystal structures of antibody Fab fragments of HLA-A2 / b2m binding to display HPV16E7:11-19 peptides were determined. One structure contained 17670P Fab and the other contained 17363N Fab; together, these two structures covered the sequence space of the six antibodies presented above (e.g., Tables 11 and 12). All nine residues of the HPV16E7:11-19 peptide displayed by this HLA are clearly visible in the electron density maps of both the 17670P and 17363N structures. Even in At this resolution (17670P structure), the positions and identities of peptide residues are unambiguous, and residue-residue interactions can be accurately determined. Allows for improved accuracy.
[0351] The 17670P and 17363N Fabs bind to the top of the HLA-peptide complex in a manner very similar to that of TCR binding. The Fabs are positioned and oriented almost identically to each other; both are aligned fairly parallel to the "track" close to the peptide binding groove, and both are centered on the bound peptide, with the heavy chain CDRs contacting the N-terminal half of the bound peptide and the light chain CDRs contacting the C-terminal half of the peptide. Other published antibody complex structures (e.g., PDB codes 1W72 and 4WUU) reveal that the antibody does not have to cover the entire HLA-displayed peptide. However, these antibodies with only partial peptide coverage have poor specificity, tolerating extensive changes in the portion of the peptide that is not contacted with little loss of binding affinity.
[0352] The structures show that the 17670P and 17363N Fab heavy chains contact residues 11, 14, 15 in the HPV16 E7 peptide, while the Fab light chain contacts residues 15, 17, 18. No Fab contacts are made with the side chains of residues 12, 13, 16, or 19 because they point toward the HLA molecule. The bound peptides are numbered according to the residue positions in the original HPV16 E7 protein as follows:
[0353] YMLDLQPET (SEQ ID NO: 358) 11 12 13 14 15 16 17 18 19
[0355] Most Fab contacts are made with peptide side chains rather than the backbone.
[0356] Peptide contacts made by 17670P are almost exclusively concentrated in CDR LCDR1 and HCDR3, particularly HCDR3. In particular, Fab heavy chain residues 100, 101, 102, 105, 109, 110 of SEQ ID NO: 34 and light chain residues 30, 31, 32, 50 of SEQ ID NO: 42 contact the bound peptide, while Fab heavy chain residues 28, 31, 32, 100, 102, 104, 109, 110, 113 of SEQ ID NO: 34 and light chain residues 31, 50, 52, 53, 54, 55, 92 of SEQ ID NO: 42 contact HLA. "Contact" herein may involve direct or water-mediated hydrogen bonds, charge-charge interactions, or hydrophobic / van der Waals interactions. For 17363N, Fab heavy chain residues 102, 103, 108, 111, 112 of SEQ ID NO:506 and light chain residues 28, 30, 32, 50, 68 of SEQ ID NO:514 contact the bound peptide, while Fab heavy chain residues 28, 32, 100, 102, 103, 107, 112 of SEQ ID NO:506 and light chain residues 31, 49, 50, 51, 52, 53, 55, 92 of SEQ ID NO:514 contact the HLA molecule.
[0357] Among these six anti-HLA-A2:HPV16E7:11-19 antibodies, 17675P is the most similar to 17670P in terms of the CDR sequence that determines peptide binding, and 21064P and 17930N2 also share a high degree of peptide binding CDR region similarity. The key contacts between 17670P and the HLA-peptide complex are mainly conserved in 17675P, 21064P and 17930N2, so these antibodies may bind in the same way as 17670P.
[0358] In contrast, the CDR H3 of 17363N has a very different sequence than the CDR H3 from 17670P, and this sequence difference translates into structural differences in the CDR H3, altering the contacts with the HLA-peptide complex in this region. For example, heavy chain Tyr 100 in 17670P contacts Tyr 11 of the bound peptide. The equivalent residue in 17363N is Tyr 102 (the CDR H3 of this antibody is two residues longer), and this residue does not contact peptide Tyr 11. Instead, Tyr 102 has been reoriented to contact a nearby HLA molecule.
[0359] Lead antibody 17364N has a very similar sequence to 17363N and is identical in all residues that contact the HLA-peptide complex. This antibody should have a very similar binding mode to 17363N and thus be different from 17670P, 17675P, 17930N2 and 21064P.
[0360] The scope of the present invention is not limited by the specific embodiments described herein. In fact, in addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art based on the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. An isolated antigen-binding protein that specifically binds to a conformational epitope of an HLA-A2-presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), wherein the conformational epitope comprises one or more amino acids selected from Y11, D14, L15, P17 and E18 of SEQ ID NO:
537.
2. The isolated antigen binding protein of claim 1, wherein the antigen binding protein has a property selected from the group consisting of: (a) with a binding dissociation equilibrium constant (K) of less than about 20 nM as measured in a surface plasmon resonance assay at 25°C. D ) binds to monomeric HLA-A2:HPV16E7 11-19 peptide; (b) with a binding dissociation equilibrium constant (K) of less than about 25 nM as measured in a surface plasmon resonance assay at 25°C. D ) binds to monomeric HLA-A2:HPV16E7 82-90 peptide; (c) with an EC of less than about 6 nM as determined by luminescence assay 50 Binds to cells expressing the HLA-A2:HPV16E7 11-19 peptide and does not bind to cells expressing predicted off-target peptides; (d) with an EC of less than about 1 nM as determined by luminescence assay 50 binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide, and does not substantially bind to cells expressing predicted off-target peptides; (e) with an EC of less than about 30 nM as determined by flow cytometry assay 50 Binding to HLA-A2:HPV16E7 11-19 peptide expressing cells; and (f) with an EC of less than about 75 nM as determined by flow cytometry assay 50 Binds to HLA-A2:HPV16E7 82-90 peptide expressing cells.
3. The isolated antigen-binding protein of claim 1, wherein the HPV16 E7 peptide comprises the amino acid sequence of YMLDLQPET (SEQ ID NO: 538).
4. The isolated antigen binding protein of any one of claims 1-3, wherein the antigen binding protein is a full-length antibody, Fab, Fab', (Fab')2, Fv, single-chain Fv (scFv), T-body construct or CAR.
5. The isolated antigen binding protein of any one of claims 1-4, wherein the antigen binding protein is a human monoclonal antibody, or an antigen binding fragment thereof.
6. The isolated antigen-binding protein of any one of claims 1 to 5, comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the light chain variable region (LCVR) sequences listed in Table 1.
7. The isolated antigen binding protein of any one of claims 1-6, comprising a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1.
8. The isolated antigen binding protein of any one of claims 1-7, comprising a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
9. The isolated antigen binding protein of any one of claims 1-8, comprising: (a) a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1; and (b) a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
10. The isolated antigen-binding protein of any one of claims 1-9, comprising: (a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508 and 524; (b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, 382, 414, 430, 446, 462, 478, 494, 510 and 526; (c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512 and 528; (d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516 and 532; (e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518 and 534; and (f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520 and 536.
11. The isolated antigen binding protein of claim 10, comprising a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 2 74, 282 / 290, 298 / 306, 314 / 322, 330 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514 and 522 / 530.
12. The isolated antigen binding protein of claim 11, comprising a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10, 34 / 42, 82 / 90, 194 / 202, 282 / 290 and 506 / 514.
13. An isolated antigen binding protein that competes for binding with the antigen binding protein of claim 11.
14. An isolated antigen binding protein that binds to the same epitope as the antigen binding protein of claim 11.
15. The isolated antigen binding protein of any one of claims 1-14, comprising a detectable moiety.
16. A pharmaceutical composition comprising the isolated antigen-binding protein of any one of claims 1 to 15, which binds to HLA-A2:HPV16E7, and a pharmaceutically acceptable carrier or diluent.
17. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR of the antigen binding protein of any one of claims 1-15.
18. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the LCVR of the antigen binding protein of any one of claims 1-15. A vector comprising the polynucleotide molecule according to claim 17 or 18.
20. A cell expressing the vector of claim 19.
21. A method for treating a subject suffering from a disease or condition associated with HPV16 E7, comprising administering to the subject a therapeutically effective amount of the antigen binding protein of any one of claims 1 to 15 or the pharmaceutical composition of claim 16, thereby treating the subject.
22. The method of claim 21, wherein the HPV16E7-related disease or disorder is an HPV-related cancer.
23. The method of claim 22, wherein the HPV-related cancer is squamous cell carcinoma.
24. The method of claim 23, wherein the HPV-related cancer is cervical cancer, anorectal cancer, head and neck cancer, or oropharyngeal cancer.
25. The method of any one of claims 21-24, wherein the antigen binding protein is administered to the subject in combination with a second therapeutic agent.
26. The method of claim 25, wherein the second therapeutic agent is selected from a PD-1 inhibitor, a CTLA-4 inhibitor, an antibody against a tumor-specific antigen, an antibody against an antigen on a virus-infected cell, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a dietary supplement such as an antioxidant, a VEGF antagonist, a chemotherapeutic agent, a cytotoxic agent, surgery, radiation therapy, an NSAID, a corticosteroid, an anti-HPV vaccine, and any other therapy that can be used to alleviate at least one symptom associated with the disease or condition.
27. The method of any one of claims 21-26, wherein the antigen binding protein is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.
28. The method of any one of claims 21-27, wherein the antigen binding protein is administered at a dose of about 0.1 mg / kg to about 100 mg / kg body weight of the subject.
29. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular binding domain that specifically binds to a conformational epitope of HLA-A2 presenting human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide), a transmembrane domain, and an intracellular signaling domain.
30. The isolated nucleic acid molecule of claim 29, wherein the extracellular binding domain is an anti-HLA-A2:HPV16E7 antigen binding protein.
31. The isolated nucleic acid molecule of claim 30, wherein the isolated antigen binding protein comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within any one of the light chain variable region (LCVR) sequences listed in Table 1.
32. The isolated nucleic acid molecule of claim 30 or 31, wherein the isolated antigen binding protein comprises a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1.
33. The isolated nucleic acid molecule of any one of claims 30-32, wherein the isolated antigen binding protein comprises a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
34. The isolated nucleic acid molecule of any one of claims 30-33, wherein the isolated antigen binding protein comprises: (a) a HCVR having an amino acid sequence selected from the HCVR sequences listed in Table 1; and (b) a LCVR having an amino acid sequence selected from the LCVR sequences listed in Table 1.
35. The isolated nucleic acid molecule of any one of claims 30-34, wherein the isolated antigen-binding protein comprises (a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508 and 524; (b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, 382, 414, 430, 446, 462, 478, 494, 510 and 526; (c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512 and 528; (d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516 and 532; (e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518 and 534; and (f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520 and 536.
36. The isolated nucleic acid molecule of any one of claims 30-35, wherein the isolated antigen binding protein comprises a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 2 74, 282 / 290, 298 / 306, 314 / 322, 330 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514 and 522 / 530.
37. The isolated nucleic acid molecule of any one of claims 30-32, wherein the isolated antigen binding protein comprises a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10, 34 / 42, 82 / 90, 194 / 202, 282 / 290 and 506 / 514.
38. The isolated nucleic acid molecule of any one of claims 30-37, comprising any one of SEQ ID NO: 540, 541, 542, 543, 544 or 545.
39. The isolated nucleic acid molecule of any one of claims 30-38, wherein the isolated antigen binding protein is a scFv.
40. A vector comprising the isolated nucleic acid molecule of any one of claims 30-39.
41. An isolated immune effector cell comprising the vector of claim 40.
42. The isolated immune effector cell of claim 41, which is a T body.
43. A method of treating a subject having an HPV-related disease or condition comprising administering to the subject the immune effector cell of claim 41 or 42.
44. The method of claim 43, wherein the HPV-related disease or condition is an HPV-related cancer.
45. The method of claim 44, wherein the HPV-related cancer is squamous cell carcinoma.
46. The method of claim 45, wherein the HPV-related cancer is cervical cancer, anorectal cancer, head and neck cancer, or oropharyngeal cancer.
47. The method of any one of claims 43-46, wherein the antigen binding protein is administered to the subject in combination with a second therapeutic agent.
Citation Information
Patent Citations
Re-activated T-cells for adoptive immunotherapy
US20030170238A1
Modification assisted profiling (MAP) methodology
US20040101920A1
Readily Isolated Bispecific Antibodies with Native Immunoglobulin Format
US20100331527A1
Antibodies comprising chimeric constant domains
US20140243504A1
Engineered gamma delta t-cells
US20160175358A1
